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Glycosidases are amongst the most abundant enzymes in nature. This is due to their role in the 
degradation of carbohydrates which are the major source of carbon or earth. The absence or 
malfunction of glycosidases is implicated in numerous diseases such as cancers, diabetes, and 
lysosomal storage disorders, which make them important drug targets for study in medicinal 
chemistry. The seminal work by Pauling and Wolfenden showed that enzymes bind to their 
substrate at the transition state with very strong affinity. Wolfenden estimated the dissociation 
constant to be around 10-22M. This encouraged the design of glycosidase inhibitors which 
mimicked one or more features of the transition state. The notable features of the transition state 
of glycosidases include the development of a positive charge on the anomeric carbon atom, and 
the distortion of the sugar ring into one of a boat, an envelope, or a half-chair conformation to 
accommodate the formed positive charge.  
The glyconoamidine family of inhibitors emerged as a class of compounds to mimic both the 
positive charge and distorted chair conformation of the transition state of glycosidases. Research 
in the Striegler group identified a library of galactonoamidines as highly potent competitive 
inhibitors of several β-galactosidases, with inhibition constants in the low nanomolar to 
picomolar range. The work described here summarizes an effort towards the synthesis of polar 
and bulky galactonoamidines for the inhibition of the human α-galactosidase. Following a 
protocol previously established in the group, the precursor galactothionolactam was synthesized 
and coupled with several amines to yield a library of perbenzylated galactonoamidines. 
Hydrogenation of the perbenzylated galactonoamidines in the presence of palladium on carbon 
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1: Carbohydrates and Carbohydrate Processing Enzymes 
1.1: Introduction 
Carbohydrates along with their corresponding glycoconjugates are the most abundant 
class of biomolecules exiting in nature, and account for a significant portion of the carbon atoms 
on earth.1 These biomolecules play very crucial roles that are responsible for the sustainability of 
life in living organisms. Some of the established roles of carbohydrates in biological systems 
include but are not limited to energy production and metabolism,2 provision of structure and 
support,3 protein quality check,4 cell recognition,5 and cell signalling. Moreover, overexpression 
of certain carbohydrates in cells serve as biomarkers for the onset or progression of diseases.6 
For example, an increase in serum levels of CA242 antigen is clinically used as a diagnostic 
biomarker for colorectal, pancreatic, and other cancers.7, 8 Glycosyl transferases and glycoside 
hydrolases are the enzymes responsible for the build-up and breakdown of complex 
carbohydrates in cells. These enzymes regulate the amounts of carbohydrates and 
glycoconjugates in biological systems and are therefore crucial for cell regulation and function. 
The absence or malfunction of carbohydrate processing enzymes are well known to result in 
diseases such as cancers, diabetes, and lysosomal storage disorders. Therefore, these enzymes are 
interesting targets for drug discovery in medicinal chemistry.6, 9 While both enzymes play very 
critical roles and are important targets for drug discovery, the discussion here is limited to 
glycoside hydrolases for brevity. Glycoside hydrolases (GH) also known as glycosidases are 
currently classified into 168 families based on the similarity of their amino acid sequence. The 
GH families are also grouped into 18 clans based on the conservation of the overall three-
dimensional topology and amino acid sequence around the enzyme active site.10-12 Enzymes 
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belonging in the same family typically employ a similar mechanism for the hydrolysis of their 
substrates. 
1.2: Mechanisms of Glycoside Hydrolases 
The mechanism for the hydrolysis of glycosides proposed by Koshland in 1953 involves 
the retention or inversion of stereochemistry at the anomeric carbon atom, with an oxocarbenium 
ion-like transition state.13, 14 There is ample experimental evidence in support of the existence of 
an oxocarbenium ion-like transition state during the hydrolysis of glycosides using techniques as 
nuclear magnetic resonance spectroscopy (NMR),15, 16 mass spectrometry,17, 18 13C kinetic 
isotope effect studies,19 and infrared ion spectroscopy.20, 21 The transition state is characterized 
by a build-up of positive charge between atoms C1-O5, which is accommodated by the distortion 
of the sugar ring away from the typical chair conformation Figure 1.1.13, 22 
 
Figure 1.1: A general structure of the transition state of glycoside hydrolases. 
The glycosidases that utilize the inversion or retention mechanism for the hydrolysis of their 
substrate employ either an aspartate or a glutamate amino acid as the catalytic residue.23 In the 
inversion mechanism, one of the catalytic residues acting as an acid protonates the exocyclic 
oxygen Figure 1.2A. Next a water molecule deprotonated by the other catalytic residue attacks 
the anomeric carbon atom, resulting in the cleavage of the C-O bond.13, 24 The retention 
mechanism is a double displacement process, which occurs in two steps Figure 1.2B. In the first 
step, the exocyclic oxygen is protonated by a catalytic residue, followed by a nucleophilic attack 
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of the second catalytic residue on the anomeric carbon atom, forming a glycosyl-enzyme 
intermediate, with the cleavage of the C-O bond, and one face of the sugar blocked from 
nucleophilic attack. In the next step, a catalytic residue deprotonates a water molecule which 
attacks the anomeric carbon atom from the exposed face, resulting in a product with a retained 
configuration at the anomeric carbon atom.13, 24 
 
Figure 1.2: The Koshland inversion and retention mechanism for the hydrolysis of glycosides. 
 
Over the years, more in-depth mechanistic studies of several glycoside hydrolase families have 
revealed several variants of the Koshland mechanism. For example, some N-
acetylhexosoaminidases (NAGases) from families 18 and 20 which cleave N-acetyl-β-
hexosaminidines during glycoprotein biosynthesis have be shown to operate through a substrate 
assisted mechanism.25 In this mechanism, the exocyclic oxygen of the glycoside is protonated by 
a catalytic residue, followed by a nucleophilic attack of the anomeric carbon atom by the 
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carbonyl oxygen atom of the N-acetamido group, forming an oxazoline intermediate Figure 
1.3A. In the next step, a water molecule deprotonated by a catalytic residue attacks the anomeric 
carbon atom to form the hydrolysis product with a retention of configuration.25, 26 Several 
glycosidases such as sialidases and trans-sialidase belonging to glycoside hydrolase families 33, 
34 and 143 are known to utilize an unusual nucleophile for the hydrolysis of their substrate. 
Enzymes in these glycoside hydrolase family use a tyrosine residue as the nucleophile instead of 
the commonly utilized aspartate or glutamate residue.26 In this mechanism the exocyclic oxygen 
of the sialic acid is first protonated by an acidic catalytic residue Figure 1.3B. Subsequently, a 
nearby glutamate residue deprotonates a tyrosine residue which then attacks the anomeric carbon 
atom. Hydration of the formed intermediate by a deprotonated water molecule then affords the 
hydrolyzed product with a retention of configuration at the anomeric carbon atom.27, 28 Also, α-
mannosidase from glycoside hydrolase family 99 was found to catalyze its substrate via an 
epoxide intermediate formed between the C2-hydroxyl group and the anomeric carbon atom 
Figure 1.3C.29 Here, the exocyclic oxygen is first protonated by a catalytic residue, 
subsequently, a nearby glutamate residue deprotonates the hydroxyl group on carbon 2, resulting 
in a nucleophilic attack at the anomeric carbon atom and the departure of the leaving group, and 
forming an epoxide intermediate. Next the epoxide oxygen is protonated by a carboxylate 
residue and the epoxide ring is opened by an attack of a deprotonated water molecule, yielding 
the hydrolyzed product with a retention of configuration at the anomeric carbon atom.29, 30 
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Figure 1.3: Non-Koshland mechanisms for the hydrolysis of glycosides. 
 
It is now well established in the field that the hydrolysis of glycosides proceeds through a 
transition state with strong oxocarbenium ion-like character, with a delocalization of the positive 
charge between atoms C1-O5.15, 31 The development of the positive charge is accommodated by 
conformational changes of the sugar ring away from the typical chair (4C1) conformation into a 
more planar or distorted conformation as it approaches the transition state.23, 32 The reaction 
itineraries of numerous glycoside hydrolase families have been mapped out, by using a 
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combination of enzyme inhibition studies,33 computational analysis,26 and X-ray diffraction 
analysis.34 A combination of these studies can be used to decipher the mechanism as well as 
predict the conformation of the enzyme bound substrate as it goes from the Michaelis-complex to 
the transition state and finally to the covalent intermediate.35, 36 Since the transition state cannot 
be trapped, it can be predicted from the obtained conformations of the Michaleis-complex and 
the covalent intermediate by analysis of the Cremer-Pople coordinate,37 which outlines the 
pathways for sugar puckering in combination with metadynamics simulations.35 Mechanistic 
studies of numerous glycoside hydrolases have revealed the most common transition state 
conformations to be a half-chair (H), boat (B) or envelope (E) conformation.22 The knowledge 
and understanding of glycoside hydrolase mechanism and reaction conformational itinerary have 
proved useful for the development of potent and selective glycosidase inhibitors.38 
 
1.3: Mechanism based Inhibitors of Glycoside Hydrolases 
Pauling postulated that the highest affinity inhibitors were those which mimicked the 
features of the transition state of the enzyme.39 The seminal work by Wolfenden revealed 
glycosidases hydrolyzed their substrates with a rate enhancement of over 1017 -fold over the non-
catalyzed reaction.40 This translates to a binding constant of the transition state to be around 10-
22M.41 This propelled the design of glycosidase inhibitors mimicking the features of the transition 
state of glycoside hydrolases. The design of glycosidase inhibitors was primarily focused on the 
two key features (i) inhibitors mimicking the positive charge of the transition state and (ii) 
inhibitors mimicking the shape or conformation of the transition state. Azasugar inhibitors such 
as nojirimycin 1 become protonated under physiological conditions to mimic the positive charge 
of the transition state of glycoside hydrolase Figure 1.4. Other inhibitors nitrogen containing 
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inhibitors such as, deoxynojirimycin 2, isofagomine 3, noeuromycin 4, azafagomine 5, 
castanospermine 6 and calystegine B2 7 have also been demonstrated to have modest to good 
inhibitory activities towards glycosidases with IC50 or inhibition constant (Ki) values in the low 
micromolar range. Their activity is attributed to their ability to become protonated under 
physiological conditions hence mimicking the positive charge of the transition state. 
 
Figure 1.4: Glycosidase inhibitors mimicking the positive charge of the transition state. 
 
Likewise, compounds mimicking the distorted chair conformation of the transition state such as 
gluconolactone 8, gluconolactam 9, isofagomine lactam 10, glucotetrazole 11, mannotetrazole 12 
and glucoimidazole 13 have also been demonstrated to be potent inhibitors of glycosidases with 
IC50 and or Ki values in the micromolar to nanomolar range Figure 1.5. Indeed mannotetrazole 
12 with a B2,5 conformation has been experimentally proven to be a true transition state mimic of 
β-mannosidase from Bacteroides thetaiotaomicron, through linear free energy relationship 
analysis.42 Early discussions in the literature focussed on establishing which feature was most 
essential for the binding of the inhibitors to the enzyme and was also the subject of several 
reviews.43-45 While there is no definite conclusion as to whether the shape or the charge 
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contribution is more important for the binding of the inhibitors to the enzyme, studies now show 
that the preference for either the shape or charge contribution was enzyme dependent.30 
Moreover, recent studies are showing that the potency of glycosidase inhibitors goes beyond the 
shape and charge contribution but also includes other factors such as the ability of the inhibitor to 
have favorable interactions with the enzyme.46, 47 
 
Figure 1.5: Glycosidase inhibitors mimicking the distorted chair conformation of the transition 
state. 
 
To harness more binding affinity by transition state mimicry, Ganem and co-workers pioneered 
the synthesis of the glyconoamidine family of inhibitors which possesses a distorted chair 
conformation, and is protonated under physiological conditions to developing a positive charge 
to mimic the features of the transition state of glycoside hydrolase.48-50 that combine the shape 
and charge mimicry of the transition state. Synthesis and evaluation of gluconoamidines 14 a-d. 
against a panel of glycosidases revealed them to be potent broad-spectrum inhibitors with 
inhibition constant in the low micromolar to high nanomolar range Figure 1.6 48, 50 The potency 
of the inhibitors is attributed to their close mimicry of the features of the transition state of 
glycoside hydrolases. Moreover, the gluconoamidines displayed higher selectivity for the 
inhibition of glucosidase and a slightly weaker inhibition of mannosidase whereas the inhibition 
of the galactosidase was significantly lower, indicating configuration of the inhibitor contributes 
to the selectivity of the inhibitors.  
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Figure 1.6: Structures of gluconoamidine inhibitors synthesized by Ganem and co-workers. 
 
However, Tellier and coworkers noted that the gluconoamidines 14a-d synthesized by Ganem 
did not take advantage of an aglycon interaction with the active site residues. Mannoamidine 15a 
without a benzyl aglycon and mannoamidine 15b with a sugar aglycon were synthesized and 
evaluated as inhibitors of several glycosidases Figure 1.7.51, 52 Compound 15a was shown to be a 
potent inhibitor of both α-mannosidase (jack bean) and β-mannosidase (snail) with inhibition 
constants of 0.55 μM and 6.0 μM respectively. On the other hand, 15b was found to be a potent 
inhibitor of α-mannosidase (jack bean) with an inhibition constant of 2.6 μM and poor inhibitor 
of β-mannosidase (snail) with Ki of 120 μM. Compound 15a was also a potent inhibitor of β-
glucosidase (sweet almond), with Ki of 5 μM, whereas 15b was a less potent inhibitor of β-
glucosidase (sweet almond) with Ki of 100 μM. The result obtained from this study revealed a 
contribution of the aglycon towards the potency and selectivity of the inhibitors towards the 
investigated glycosidases. 
 
Figure 1.7: Structures of mannoamidine inhibitors synthesized by Tellier and co-workers. 
 
Heck and coworkers also synthesized a small library of N-substituted gluconoamidines 14e-h 
and mannoamidines 15c-f with polar aliphatic side chains with varying lengths Figure 1.8.53 
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gluconoamidines 14 e-h were potent inhibitors of both α- and β- glucosidase with inhibition 
constants of 32 μM, 14 μM, 39 μM and 31 μM for the inhibition of α-glucosidase (yeast) and 34 
μM, 71 μM, 50 μM and 20 μM for the inhibition of β-glucosidase (sweet almond). The evaluated 
gluconoamidines showed no clear selectivity for either the α- or β-glucosidase. Interestingly, the 
gluconoamidines showed stronger inhibition of α- and β-mannosidase. Compound 14e inhibited 
the enzymes with Ki values of 0.06 μM for the α-mannosidase (jack bean) and 1.3 μM for β-
mannosidase (snail). Mannoamidines 15c-f were much stronger inhibitors of the α- and β- 
mannosidases with inhibition constants of 6 nM, 19 nM, 12 nM and 80 nM for the inhibition of 
α-mannosidase (jack bean) and 9 nM, 150 nM, 60 nM and 150 nM for the inhibition of β-
mannosidase (snail). Despite being a strong inhibitor of both mannosidases, compound 15c, only 
showed modest or weak inhibition of other glycosidases, making it selective for the inhibition of 
mannosidases. The inhibition constants of 15c obtained for the inhibition of other enzymes are as 
follow; 81 μM (α-glucosidase yeast), 6600 μM (β-glucosidase almond), 218 μM (α-galactosidase 
green coffee bean), 82 μM (β-galactosidase Aspergillus oryzae).  
 
Figure 1.8: N-alkyl gluco- and manno-amidines. 
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1.4: Galactonoamidines as putative transition state analog inhibitors of β-galactosidases 
A major research focus in the Striegler lab aims to develop macromolecular catalysts for 
the efficient transformations of carbohydrates. Along these lines, a series of binuclear copper (II) 
complex were designed and shown to discriminate between related sugars including epimers and 
anomers.54-56 These catalysts were also shown to catalyze the oxidation of sugars,57 as well as for 
the hydrolysis of glycosides.58 The immobilization of the binuclear copper complexes into a 
polyacrylate microgel was shown to significantly enhance their catalytic properties, due to the 
stabilizing contributions of the matrix.59, 60 moreover, templating the microgels with a ground 
state sugar also resulted in an improved catalytic efficiency. To further improve the efficiency of 
the polyacrylate microgels, it was envisaged that templating them with a transition state analog 
instead of a ground state analog would facilitate the distortion of the substrate into a transition 
state geometry, hence accelerating the hydrolysis of the glycosides. This ultimately led the group 
to search for transition state analog of glycosidases, with β-galactosidase being the model 
enzyme. In addition, the deficiency of functional lysosomal β-galactosidase results in a 
lysosomal storage disorder known as GM1-gangliosidosis.61 Therefore, the development of a 
potent transition state analog inhibitor of β-galactosidase would serve a dual purpose, as both a 
potential therapeutic for the treatment of GM1-gangliosidosis,61 and as a template for the 
development of carbohydrate transforming microgels.62 As a result, research in the Striegler 
group in past decade has focussed on the synthesis and evaluation of galactonoamidines 16 as 
inhibitors of β-galactosidases. The evaluated compounds were shown to be highly potent 
inhibitors of several β-galactosidases. An initial evaluation of a small library of N-aryl 
galactonoamidines revealed these compounds to be highly potent and competitive inhibitors of β-
galactosidase (A. oryzae) with inhibition constants ranging from 12-48 nM.63 The result obtained 
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from this study prompted a more in-depth evaluation of the compounds as transition state 
analogs for the hydrolysis of glycosides by a β-galactosidase.58 Strongly binding inhibitors are 
not necessarily true transition state analogs.41, 64 Experimental methods must be provided in 
support of true transition state mimicry. Some of the methods which have been used to examine 
transition state mimicry include: X-ray diffraction analysis of enzymes complexed with 
inhibitors locked in a specific configuration,65 evaluating the binding of a substrate to an enzyme 
with a mutated active site,66 and spectroscopic analysis.67 The spectroscopic analysis, the linear 
free energy relationship analysis method established by Bartlett measures the effect of equivalent 
structural perturbations on the affinity of the true transition state and on the affinity of the 
transition state analog.67, 68 Therefore, a plot of (kcat/KM) versus Ki should give a straight line with 
a slope and correlation (R2) of 1.67 The galactonoamidines synthesized by the Striegler group 
were evaluated as transition state analogs for the hydrolysis of aryl-galactopyranosides 17 by β-
galactosidase (A. oryzae).58 Despite all compounds bearing a benzyl aglycon, only 16a with a 
para-methyl substituent on the aglycon was determined to be a true transition state analog.58 The 
result indicates that subtle differences in the structures of the inhibitor results in different 
interactions between the inhibitor and the amino acid residues in the enzyme active site. 
Compound 16a with a p-methyl substituent had an inhibition constant of 8 nM and was also 
experimentally determined to be a true transition state analog for the enzyme. Whereas 16b and 
16c with m-methyl and o-methyl substituent had inhibition constants of 29 nM and 23 nM 
respectively but were not true transition state analogs but fortuitous binders. All compounds are 
potent competitive inhibitors of the β-galactosidase (A. oryzae), however, the positioning of the 
methyl group on the inhibitor allows for the appropriate hydrophobic interaction which makes 
16a a true transition state analog. The compound library was further expanded to include 
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compounds possessing linear aliphatic aglycons such as 16d, and cyclic aliphatic aglycon such as 
16e Figure 1.9.69 All compounds in the 22-compound library were determined to be competitive 
inhibitors of β-galactosidase (A. oryzae) with Ki values ranging from 8-600 nM. As expected, the 
variation in the aglycons resulted in slight differences in the observed inhibition constant values, 
revealing an interplay between steric, electronic, hydrophobic, and π-π stacking interactions 
between the inhibitors and the amino acid residues of the enzyme.  
 
Figure 1.9: Structures of some previously evaluated N-aryl and N-alkyl Galactonoamidines. 
 
The same library of compounds was found to be excellent inhibitors of β-galactosidase (E. coli) 
with Ki values ranging from 0.03 – 2.6 nM, with slight variations depending on the nature of the 
aglycon.70 Compound 16a was a strong inhibitor of the enzyme with a Ki value of 0.06 nM.
71 
Derivation of the glycon of 16a afforded compounds 16g-i with either a methoxy substituent or a 
deoxy sugar derivative Figure 1.10.71 The absence of the C2-OH group in 16g resulted in a Ki 
value of 1.3 nM, a 21-fold increase from the parent compound. This agrees with the work done 
by others which shows the importance of the C2-OH for transitions state stabilization.72-74 When 
the hydroxyl group at C2 or C4 is replaced with a methoxy substituent, Ki of 42 nM and 32 nM 
are obtained, which are 700- and 530- fold increase respectively from the parent compound 16a 
Molecular docking analysis revealed the sterically hindering methoxy groups repelled the 
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inhibitors away from the active site of the enzyme.71 Although compounds 16g-i are still 
competitive inhibitors, the study reveals a strong contribution of hydrogen bonding interaction 
towards the inhibition of the enzyme. 
 
Figure 1.10: Structures of galactonoamidines with derivations in the glycon. 
 
Next, the galactonoamidines were evaluated as inhibitors of β-galactosidase (bovine liver) and 
also found to be highly potent inhibitors of the enzyme with Ki values ranging from 0.05 – 2.34 
nM.75 To understand how the galactonoamidines achieved such high potency, molecular 
dynamics simulations were performed with a few of the inhibitors and the enzyme.75 Compounds 
16g (Ki = 0.05 nM), 16i (Ki = 1500 nM) and 16k (Ki = 2000 nM) were chosen for the study. 
Compound (16f) was found to reside within the active site of the enzyme, had significant 
hydrogen bonding interaction with the amino acid residues of the enzyme active site, and 
interacted with both catalytic residues of the enzyme: proton donor (Glu-187) and nucleophile 
(Glu-267) throughout the simulation. Moreover, a loop closure event supported by π-π stacking 
interaction of the aromatic aglycon and Trp-272 and Tyr-484 was observed, which stabilized the 
protein upon binding of the inhibitor. The simulation reveals compound 16h is pushed out of the 
enzyme active site due to steric repulsion by the methoxy group at C2, only interacts with the 
nucleophile (Glu-267) and has slightly fewer hydrogen bonding interactions with the amino acid 
residues of the active site. On the other hand, compound (16j) without an aglycon was unable to 
induce the loop closure movement, and ultimately resulted in significantly lower hydrogen 
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bonding interactions. The structure activity relationship study and the computational analyses of 
galactonoamidines with several β-galactosidases reveal the exceptional potency to be due to a 
synergy of interactions between the inhibitors and the enzymes.  
 
2: Designing galactonoamidines for the inhibition of the human α-galactosidase. 
2.1: Introduction 
The exceptional potency of galactonoamidines towards the inhibition of β-galactosidases 
encouraged us to explore their activity towards α-galactosidases. The human α-galactosidase is a 
lysosomal glycosidase responsible for the cleavage of the α-galactosyl moiety of 
globotriaosylceramide in the lysosome, hence enabling its degradation Figure 2.1.76, 77 The α-
galactosidase is synthesized in the endoplasmic reticulum and then transported to the lysosome 
where it performs it functions.78 However, several mutations in the gene encoding the α-
galactosidase are known to result in an improper folding of the protein, which leads to a failed 
protein quality check and prevents transportation to the lysosome. The absence of lysosomal α-
galactosidase results in the accumulation globotriaosylceramide in plasma and tissue.79, 80 This 
eventually reaches a toxic level resulting in organ damage such as heart failure, kidney 
malfunction and stroke.81 This is a condition known as Fabry disease.82 Enzyme replacement 
therapy is common method for the treatment of lysosomal storage disorders such as Fabry 
disease, where the patients are intravenously supplied with the enzyme.83 
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Figure 2.1: Structure of globotriaosylceramide responsible for Fabry disease. 
This method of treatment is expensive and prompted the search for other viable treatment 
methods such as substrate reduction therapy,84, 85 and pharmacological chaperone.86, 87 The 
substrate reduction therapy uses a small molecule inhibitor to reduce the synthesis of the 
glycosphingolipid, whereas the pharmacological chaperone therapy uses an inhibitor to stabilize 
the unfolded protein and allow its transportation to the lysosome.6, 9 Competitive inhibitors of α-
galactosidase such as 1-deoxygalactonojirimycin 17a88 and several of its derivatives; α-
homogalactonojirimycin 17b,89 α-homoallonojirimycin 17c,90 and β-1-C-butly-
deoxygalactonojirimycin 17d,91 Figure 2.2 with IC50 values of 0.04 μM, 0.21 μM, 4.3 μM and 
16 μM respectively have been shown to increase the α-galactosidase activity in Fabry 
lymphoblast.92 In 2018, compound 17a was approved by the FDA as a pharmacological 
chaperone for the treatment of Fabry disease.93 This makes the evaluation of galactonoamidines 
as inhibitors of the human α-galactosidase very appealing. We expect the galactonoamidines to 
be stronger inhibitors of the human α-galactosidase than the 1-deoxygalactonojirimycin 17a 
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because, they mimic the positive charge and distorted chair (4H3) conformation of the transition 
state,62 whereas compound 17a only mimics the positive charge of the transition state.  
 
Figure 2.2: Structures of competitive inhibitors shown to improve the α-galactosidase activity in 
Fabry lymphoblast. 
Results obtained from the computational simulation of galactonoamidines with β-galactosidase 
reveal a necessity for hydrogen bonding interaction between the inhibitors and the proton donor 
and nucleophile of the enzyme active site. In this regard, the previously synthesized 
galactonoamidines could not be used as is for the inhibition of the human α-galactosidase. This is 
because compared to the previously evaluated β-galactosidases which had distances of around 
5.0Å between the catalytic residues Figures 2.3a,b,94, 95 the human alpha galactosidase has a 
distance of 8.2Å between its catalytic residues Figure 2.3c,77 which would prevent optimal 
hydrogen bonding interaction between the inhibitor and the catalytic residues of the active site. 
We therefore hypothesized that galactonoamidines with polar or bulky aglycons will be potent 
inhibitors of the human α-galactosidase. The installation of a polar functional group on the 
aglycon will increase the chances of hydrogen bonding interaction between the inhibitor the 
catalytic residues of the enzyme, whereas the installation of bulky aglycons will promote other 
favorable interactions such as π-π stacking, electrostatic or hydrophobic interactions between the 






   





Figure 2.3: Distances between the catalytic residues of galactosidases; a) β-galactosidase (A. 
oryzae), b) β-galactosidase (E. coli), c) α-galactosidase (Human).  
2.3: Synthesis of galactothionolactam 
The galactothionolactam was synthesized in 10 steps from commercially available 
galactose following procedures which were previously described by our group and others 
(Scheme 2.1). D-Galactose was treated with sodium acetate and acetic anhydride to afford the 
peracetylated galactose 18 in 74% yield.96 To protect the anomeric hydroxyl group, the resulting 
peracetylated galactose 18 was treated with p-thiocresol in the pesence of boron trifluoride to 
afford the peracetylated thiogalactoside 19 in 91% yield.97 A Zemplén deacetylation of 19 using 
a catalytic amount of sodium methoxide in methanol afforded thiogalactoside 20 in 98% yield.97 
A global benzylation of 20 in the presence of benzyl chloride, sodium hydride and a catalytic 
amount of potassium iodide afforded the perbenzylated thiogalactoside 21 in 83% yield.97 
Removal of the thiocresol group was achieved by treatment of 21 with N-bromosuccinimide in a 
9:1 v/v mixture of acetone and water to afford the perbenzylated galactopyranose 22 in 87% 
yield.98 A Swern oxidation of 22 with dimethyl sulfoxide and acetic anhydride afforded the 
perbenzylated galactonolactone 23. The endocyclic nitrogen is installed by the treatment of 23 
with a 7 M solution of ammonia in methanol to afford the hydroxy amide 24 in 68% yield after 
two steps.99 A Swern oxidation of 24 afforded the keto amide 25 in 84% yield. Reductive 
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amination of 25 using sodium cyanoborohydride and formic acid afforded a mixture of the D-
galactonolactam 26a and L-altronolactam 26b in 88% yield.100 The mixture of compounds can 
be separated by repetitive column chromatography or can be used as is for the next step. 
Treatment of 26 with Lawesson’s reagent affords a mixture of D-galactothionolactam (27a) and 
L-altrothionolactam 27b in 84% yield.62 Similarly, the mixture of isomers can be separated by 
repetitive chromatography, albeit under the risk of partial compound decomposition on silica. 
Previous study from our group have also shown that when this mixture of isomers is used for the 
next step, only 27a reacts to form the perbenzylated galactonoamidine 28.62 The overall yield for 
the synthesis from galactose is 20% 
 
Scheme 2.1: Synthesis of galactothionolactam: Reagents and conditions: i) NaOAc, Ac2O, 120 
°C, 2 h, 94%; ii) p-thiocresol, BF3.Et2O, CH2Cl2, 0 °C to rt, 6 h, 91%; iii) NaOMe, MeOH, 1 h, 
98%; iv) NaH, BnCl, DMF, rt, 18 h, 83%; v) NBS, acetone / water (9:1 v/v), rt, 5 h, 97%; vi) 
Ac2O, DMSO, rt, 19 h; vii) conc NH3 / MeOH, rt, 2 h, 68% after 2 steps; viii) Ac2O, DMSO, rt, 





   
2.4: Synthesis of amines 
Despite the failure of the molecular docking analysis to provide reliable results, polar and 
bulky galactonoamidines still seemed like a viable option for the potent inhibition of the human 
α-galactosidase. The required amines 29a-j were typically synthesized in 2-3 steps following 
literature procedures. The precursor nitriles 31a-k were assembled via one of: a Williamson-
ether synthesis 29a-f,101 cross-coupling reaction 29g-i,102 or a nucleophilic aromatic substitution 
29j.103 The precursor for 29f and 29l was obtained by successively benzylating and mesylating 
the hydroxyl groups of ethylene glycol.104, 105 The obtained intermediate was treated with sodium 
azide to afford the precursor for 29f or reacted with 4-hydroxybenzonitrile, under the conditions 
of a Williamson ether synthesis to obtain the precursor for 29l.104, 105 The corresponding amines 
were obtained in good yields by reduction of the nitrile or azide moiety using lithium aluminum 
hydride Scheme 2.2. 106 
 




   
2.5: Synthesis of perbenzylated galactonoamidines 
Following a procedure previously elaborated in the group, perbenzylated 
galactothionolactam 27a is activated by treatment with Meerwein’s salt to obtain an intermediate 
galactoiminothioether 30 (Scheme 2.3).62 Subsequently, the obtained intermediate 30 is reacted 
with freshly distilled amine to obtain the perbenzylated galactonoamidine 28 (Scheme 2.3).62 
The coupling of benzyloxybenzylamines, methoxybenzylamines and butoxybenzylamine 
proceeded as expected, yielding compounds 28a-f in modest yields. These would potentially 
yield the desired polar galactonoamidines. The coupling of a few bulky amines afforded the 
corresponding bulky perbenzylated galactonoamidines perbenzylated galactonoamidines 28g-j in 
modest yields as well (Scheme 2.3). Unfortunately, the same results could not be obtained for 
the other bulky amines which were attempted. For example, the coupling of the bipenylamines 
either yielded trace amount of the desired product or nothing at all. TLC analysis of the failed 
reactions indicated that all the galactothionolactam 27a had been transformed to the intermediate 
galactoiminothioether 30, but only very little or no transformation of 30 to the corresponding 
perbenzylated galactonoamidine 28. Several attempts at increasing the reaction time or using 4-
10 equivalents of the amine did not result in a significant improvement of the reaction outcome. 
The coupling reaction is set up under scrupulously anhydrous conditions, with amines that are 
distilled and stored under nitrogen atmosphere for no more than 24 hours prior to use, which 
rules out the possibility that the amine had been oxidized or protonated before being introduced 
to the reaction mixture. Moreover, 1H-NMR analysis of the commercial and synthesized amines 
was used to ascertain the purity of the amines prior to use. Interestingly, on several occasions, 
when TLC analysis of an aliquot of the reaction mixture indicated no significant transformation 
of product formation after 8-14 days of stirring, a different amine, typically 4-
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methylbenzylamine was added to the reaction flask, and after 16 hours of stirring, all unreacted 
intermediate 30 was transformed to the corresponding perbenzylated galactonoamidine 28q. 
Since the failure of these coupling reactions could not be attributed to poor experimental set up 
or the use of bad reagents or moisture containing solvent, the other plausible explanation would 
be difference in the reactivity of the amines under the reaction conditions. The amines that had 
failed to couple under the previously established conditions even with increased reaction times 
and amine equivalents are bulky in nature. However, the poor reactivity cannot necessarily be 
attributed to steric effect. The successful coupling of 2-methoxybenzylamine and 2-
benzyloxybenzylamine which have bulky substituents at the ortho position next to the amine 
moiety indicate the poor reactivity is possibly due to an electronic effect. Perhaps, the electron 
withdrawing phenyl rings at the para position of the biphenylamines render them less reactive 




   
Scheme 2.3: Synthesis of perbenzylated galactonoamidines 28a-k in dichloromethane. 
Next, the failed coupling reactions were repeated using acetonitrile as the solvent. This resulted 
in an overall improvement in the yields of the isolated compounds. The yield of compound 28k 
improved from a 10% in dichloromethane to a 30% when the reaction was done in acetonitrile. 
Compounds 28l-n were also now accessible, albeit in low-modest yields, which was sufficient to 
move on to the next step. In addition, 28o-p were added to the library (Scheme 2.4). 
 
 
Scheme 2.4: Synthesis of perbenzylated galactonoamidines 28k-p in acetonitrile. 
2.6: Synthesis of galactonoamidines 
Following a procedure previously described by the group, polar galactonoamidines 16k-q 
were obtained readily in excellent yields from their precursor perbenzylated galactonoamidines 
by hydrogenation in the presence of palladium on carbon, ethanol and trifluoroacetic acid, 
Scheme 2.5.62 The addition of the trifluoroacetic acid is necessary to prevent the coordination of 
palladium to the amidine site.62 NMR and HRMS analysis of the obtained compounds indicated 
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complete debenzylation occurred, and the desired compounds were obtained.  Following the 
same procedure, bulky galactonoamidines 16r-s were also obtained in high yields. The 
hydrogenation of 28h, yielded a mixture of compounds. NMR and LC-MS analysis of the 
obtained compound indicated the major product was 16t, where the indole moiety of the aglycon 
had been completely reduced to the octahydrotryptophan. The indole moiety of tryptophan in a 
peptide was reduced to an octahydrotryptophan by hydrogenation in the presence of palladium 
and formic acid.107 Unfortunately, attempts at synthesizing the other bulky galactonoamidines 
16u-z did not yield clean compounds. In all cases, the recovered compound weighed almost 
twice as much as expected, and moreover, the obtained 1H-NMR spectrum for the compounds 
either had broad signals due to the presence of residual palladium or were messy due to 
incomplete hydrogenation. The compounds were re-suspended in the ethanol-trifluoroacetic 
(freshly distilled) acid mixture and the hydrogenation was repeated several times to hopefully 
prevent the coordination of the palladium to the amidine site and allow for complete 
debenzylation. Increasing the reaction time, palladium loading or the amount of trifluoroacetic 
acid did not result in an improvement in the hydrogenation. There is no clear explanation on why 
the hydrogenation worked for some of the compounds in the library and not for others. The 
galactonoamidines 16k-z only vary in the structure of their aglycon, which doesn’t seem like it 
would affect the progression of the hydrogenation reaction. 
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3: Conclusion and outlook 
The work described here aimed to synthesize a new library of galactonoamidines with 
polar and bulky aglycons in hopes of optimizing their interactions with the human α-
galactosidase. Following a procedure previously described by the group a library of 
perbenzylated galactonoamidines were synthesized by either performing the reaction in 
dichloromethane or acetonitrile. With the perbenzylated galactonoamidines in hand, 
hydrogenation in the presence of palladium on carbon afforded nine of the desired 
galactonoamidines, while the other attempted 7 contained a significant amount of coordinated 
palladium. The purity and performance of the hydrogenation reaction could potentially be 
improved by increasing the ratio of trifluoroacetic acid to ethanol to prevent the coordination of 
the palladium. The compounds could also be potentially purified by high performance liquid 
chromatography (HPLC) on an appropriate stationary phase to avoid decomposition. 
Nonetheless, the development of galactonoamidine inhibitors for the human α-galactosidase has 
very good potential of yielding a competitive and highly potent competitive inhibitor which 
could eventually be evaluated as a pharmacological chaperone for the treatment of Fabry disease. 
1-deoxygalactonojirimycin (migalastat) a competitive inhibitor of the human α-galactosidase was 
recently approved by the FDA as a treatment for Fabry diseases. It is important to note that this 
compound only mimics the positive charge of the transition state, whereas the galactonoamidines 
with a 4H3 conformation mimics both the shape and charge of the transition state. Moreover, the 
aglycon moiety of the galactonoamidines can be derivatized to optimize the overall interactions 
between the inhibitor and the amino acid residues within the active site of the enzyme. 
Therefore, the polar and bulky galactonoamidines have the potential of becoming stronger 
inhibitors and becoming stronger pharmacological chaperones for the human α-galactosidase. 
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4: Experimental section 
4.1: Instrumentation 
NMR spectra of all compounds were measured on a Bruker 400 MHz spectrometer equipped 
with a Topspin 2.1 software. High resolution mass spectrometry data were obtained at the 
University of Arkansas statewide mass spectrometry facility. Elemental analyses were performed 
by Atlantic Micro lab, Inc. IR spectra were measured using a Shimadzu ATR-FTIR 8000 
spectrophotometer, equipped with LabSolutions IR software version 2.15. Optical rotations were 
measured on an Autopol III Automatic polarimeter using a 1.0 dm cell. Amines were distilled 
using a Bϋchi GKR-51 Kugel Rohr apparatus, under vacuum. Freeze drying was performed on a 
FreeZone 1 L bench top freeze dry system from Labconco. Melting points were measured on a 
Mel-Temp melting point apparatus, and the values are uncorrected. 
4.2: Materials and methods 
NMR measurements were done using deuterated chloroform, deuterated dichloromethane, 
DMSO-d6, acetone-d6, MeOH-d4, and deuterium oxide as solvents. The chemical shifts (δ) in the 
NMR data are expressed in parts per million (PPM) and coupling constants (J) in Hertz. The 
signal multiplicities are denoted as s (singlet), d (doublet), t (triplet), q (quartet), and m 
(multiplet). The chemical shift values are reported with respect to the residual solvents (CDCl3 
δH 7.29, δC 77.0; CD2Cl2 δH 5.32, δC 54.0; DMSO-d6 δH 2.50, δC 39.5; acetone-d6 δH 2.05, δC 
29.8; MeOH-d4 δH 4.80, δC 49.0; D2O δH 4.80, δC 49.0 after the addition of a drop of MeOH-d4). 
Column chromatography was performed on silica gel (40-63 μm, 230-450 mesh, Silicycle) or 
basic alumina (50-200 μm, 60 Å, ACROS). Thin layer chromatography (TLC) was performed on 
silica gel TLC plates from SORBENT Technologies, 200 μM, aluminum backed with 
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fluorescence indicator F254 and visualization by UV light or by charring with an ethanolic 
vanillin-sulfuric acid reagent and subsequent heating of the TLC plate. 
4.3: Chemicals 
All commercially obtained chemicals had reagent-grade quality or better and were used as 
received unless noted otherwise. 2-methoxybenzylamine, 3-methoxybenzylamine, 2-(3-
indolylethyl) amine, 2,2’-diphenylethylamine were distilled prior to use. Dichloromethane and 
diethyl ether were dried by running over neutral aluminum oxide, under a positive flow of 
nitrogen. 2-benzyloxybenzonitrile,101 3-benzyloxybenzonitrile,101 4-benzyloxybenzonitrile,108 4-
butoxybenzonitrile,109 4-phenylbenzonitrile,102 p-(p-tolyl)lbenzonitrile,102 4-cyano-4’-
fluorobiphenyl,102 4-(piperidin-1-yl)benzonitrile,103 4-cyclohexylmethoxybenzonitrile,101 (2-
azidoethoxy)methylbenzene,104, 105, 110 and 4-[2-(benzyloxy)ethoxy]benzonitrile104, 105 were 
synthesized following literature known procedures. 
 
4.4: Molecular docking analysis 
The PDB coordinates for the human α-galactosidase (PDB ID: 1R47) were obtained from the 
Protein Data Bank.111 The file was opened in PyMOL, where the substrate, water and solvent 
molecules were removed.112 The three-dimension coordinates of the protein were imported into 
PMV-1.5.6 software where the polar hydrogen atoms and Kollman charges were added to the 
atoms and converted into a pdbqt file. The galactonoamidine structures were energy minimized 
using MM2 force field and converted to pdbqt coordinate files with all non-ring bonds rotatable. 
A 30×30×30 Å3 grid box was centred in the enzyme active site. The grid dimensions and 
positions were imputed into the command prompt of AutoDock Vina 1.1.2 software,113 along 
with the pdbqt files of the galactonoamidines and the enzyme to compute the inhibitor-enzyme 
interactions with an exhaustiveness of 100. The software outputs and ranks nine inhibitor 
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conformations based on their energies. The inhibitor conformation with the lowest binding score 
was used to analyze the hydrogen bonding interactions. 
4.5: General procedure for the synthesis of amines a-m 
Lithium aluminum hydride (4.0 equiv) was transferred to a Schlenk flask and cooled in a 0 °C 
ice bath under nitrogen atmosphere for 15 minutes. Afterwards, 20-30 mL of dry diethyl ether or 
1,2-dimethoxyethane was added, followed by the corresponding azide or nitrile (1.0 equiv). The 
reaction mixture was warmed to ambient temperature and stirred for 2-40 hours. The reaction 
mixture was cooled in a 0 °C ice bath, followed by the addition of water (0.5-1 mL), 15% wt/wt 
solution of sodium hydroxide (0.5-1 mL), water (1.5-3.0 mL) and stirred for an hour. The formed 
slurry was filtered off, and the resulting solution was concentrated under reduced pressure to 
afford the crude amines which were purified by distillation using a Kugel Rohr apparatus to 
afford the title amines in good to excellent yields. 
 
2-Benzyloxybenzylamine (29a): Lithium aluminum hydride (0.94 g, 25 mmol) and 2-
benzyloxybenzonitrile (1.30 g, 6.21 mmol, 1.0 equiv) in 30 mL diethyl ether; reaction time 5 h; 
compound 29a (0.90 g, 68%) as a colorless oil; Rf = 0.12 (SiO2; CH2Cl2/MeOH; 25/1 v/v). 
1H 
NMR (400.15 MHz, CDCl3) δ 7.34 - 7.50 (m, 4H), 7.22 - 7.31 (m, 2H), 6.94 - 7.01 (m, 2H), 5.15 
(s, 2H), 3.91 (s, 2H); 13C NMR (100.6 MHz, CDCl3) δ 156.6, 137.1, 132.3, 128.6, 128.0, 127.9, 
127.1, 120.9, 111.6, 69.9, 42.7. 
 
3-Benzyloxybenzylamine (29b): Lithium aluminum hydride (0.70 g, 19 mmol) and 3-
benzyloxybenzonitrile (0.97 g, 4.6 mmol, 1.0 equiv) in 30 mL diethyl ether; reaction time 17 h; 
compound 29b (0.80 g, 81%) as a colorless oil; 1H NMR (400.15 MHz, CDCl3) δ 7.32 - 7.49 (m, 
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5H), 7.24 - 7.28 (m, 1H), 6.81 - 7.04 (m, 3H), 5.09 (s, 2H), 3.86 (s, 2H); 13C NMR (101 MHz, 
CDCl3) δ 159.1, 145.1, 137.1, 129.6, 128.5, 127.9, 127.4, 119.6, 113.6, 113.1, 69.9, 46.5 
 
4-Benzyloxybenzylamine (29c): Lithium aluminum hydride (0.40 g, 11 mmol) and 4-
benzyloxybenzonitrile (0.55 g, 2.6 mmol, 1.0 equiv) in 20 mL 1,2-dimethoxyethane; reaction 
time 21 h; compound 29c (0.90 g, 68%) as a colorless solid; m.p 110-112 °C; 1H NMR (400 
MHz, CDCl3) δ 7.33 - 7.49 (m, 5H), 7.24 - 7.28 (m, 2H), 6.96 - 7.01 (m, 2H), 5.10 (s, 2H), 3.84 
(s, 2H); 13C NMR (101 MHz, CDCl3) δ 157.7, 137.1, 135.9, 128.5, 128.2, 127.9, 127.4, 114.9, 
70.0, 45.9 
 
4-Butoxybenzylamine (29d): Lithium aluminum hydride (0.83 g, 22 mmol) and 4-
butoxybenzonitrile (0.96 g, 5.5 mmol, 1.0 equiv) in 30 mL diethyl ether; reaction time 17 h; 
compound 29d (0.69 g, 70%) as a colorless oil; 1H NMR (400.15 MHz, Acetone) δ 7.20 - 7.25 
(m, 2H), 6.82 - 6.88 (m, 2H), 4.34 (s, 1H), 3.94 - 3.99 (m, 2H), 1.69 - 1.77 (m, 2H), 1.44 - 1.55 
(m, 2H), 0.94 - 0.99 (m, 3H); 13C NMR (100.6 MHz, Acetone) δ 158.7, 134.0, 129.5, 114.9, 
68.2, 55.0, 32.1, 19.9, 14.1 
 
4-(Cyclohexylmethyoxy)benzylamine (29e): Lithium aluminum hydride (0.43 g, 11 mmol) and 
4-cyclohexylmethoxybenzonitrile (0.61 g, 2.8 mmol, 1.0 equiv) in 40 mL diethyl ether; reaction 
time 4 h; compound 29e (0.43 g, 69%) as a colorless solid; m.p 75-79 °C; 1H NMR (400.15 
MHz, Acetone) δ 7.19 - 7.25 (m, 2H), 6.82 - 6.87 (m, 2H), 4.34 (s, 1H), 3.74 - 3.79 (m, 2H), 3.71 
(s, 1H), 1.82 - 1.91 (m, 2H), 1.65 - 1.82 (m, 4H), 1.15 - 1.37 (m, 3H), 1.00 - 1.14 (m, 2H); 13C 
NMR (100.6 MHz, Acetone) δ 158.8, 134.0, 129.5, 128.9, 114.9, 73.9, 55.0, 38.6, 27.2, 26.5; 
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(FT-IR): 2933, 2850, 1508, 1241, 1029. Elemental analysis calculated for C14H21NO; C, 76.67; 
H, 9.65; N, 6.39, found C, 76.51; H, 9.57; N, 6.39. 
 
O-Benzylethanolamine (29f): Lithium aluminum hydride (0.14 g, 3.8 mmol) and 2-
benzyloxyethylazide (0.75 g, 3.0 mmol, 1.0 equiv) in 10 mL diethyl ether; reaction time 2 h; 
compound 29f (0.26 g, 68%) as a colorless oil; 1H NMR (400.15 MHz, CDCl3) δ 7.30 - 7.42 (m, 
4H), 4.57 (s, 2H), 3.53 - 3.57 (m, 2H), 2.92 (t, J = 5.26 Hz, 2H); 13C NMR (100.6 MHz, CDCl3) 
δ 138.3, 128.4, 127.7, 127.6, 73.1, 72.6, 42.0 
 
4-Phenylbenzylamine (29g): Lithium aluminum hydride (0.46 g, 12 mmol) and 4-
phenylbenzonitrile (0.54 g, 3.0 mmol, 1.0 equiv) in 30 mL diethyl ether; reaction time 16 h; 
compound 29g (0.41 g, 74%) as a colorless solid; m.p 54-56 °C; 1H NMR (400.15 MHz, CDCl3) 
δ 7.56 - 7.68 (m, 4H), 7.34 - 7.51 (m, 5H), 3.89 - 4.02 (m, 2H); 13C NMR (100.6 MHz, CDCl3) δ 
142.4, 140.9, 139.8, 128.7, 127.5, 127.3, 127.2, 127.0, 46.2 
 
4-(4’-Methylphenyl)benzylamine (29h): Lithium aluminum hydride (0.27 g, 7.2 mmol) and p-
(p-tolyl)lbenzonitrile (0.35 g, 1.8 mmol, 1.0 equiv) in 30 mL diethyl ether; reaction time 22 h; 
compound 29h (0.29 g, 81%) as a colorless solid; m.p 92-94 °C; 1H NMR (400.15 MHz, CDCl3) 
δ 7.57 - 7.62 (m, 2H), 7.50 - 7.55 (m, 2H), 7.41 (d, J = 8.31 Hz, 2H), 7.26 - 7.31 (m, 2H), 3.94 
(s, 2H), 2.43 (s, 3H); 13C NMR (100.6 MHz, CDCl3) δ 142.1, 139.7, 138.0, 136.9, 129.4, 127.5, 




   
4-(4’-Fluorophenyl)benzylamine (29i): Lithium aluminum hydride (0.35 g, 9.3 mmol) and 4-
cyano-4’-fluorobiphenyl (0.46 g, 2.3 mmol, 1.0 equiv) in 30 mL diethyl ether; reaction time 17 
h; compound 29i (0.39 g, 83%) as a colorless solid; m.p 63-64 °C; 1H NMR (400.15 MHz, 
CDCl3) δ 7.52 - 7.60 (m, 4H), 7.41 (d, J = 8.07 Hz, 2H), 7.10 - 7.19 (m, 2H), 3.95 (s, 2H); 
13C 
NMR (100.6 MHz, CDCl3) δ 163.6, 161.2, 142.4, 138.8, 137.1, 128.6, 128.5, 127.6, 127.2, 
115.7, 115.5, 46.2. 
 
4-Piperidin-1-yl-benzylamine (29j): Lithium aluminum hydride (0.84 g, 22 mmol) and 4-
(piperidin-1-yl)benzonitrile (1.03 g, 5.53 mmol, 1.0 equiv) in 42 mL diethyl ether; reaction time 
40 h; compound 29j (0.86 g, 82%) as a colorless wax; 1H NMR (400.15 MHz, CDCl3) δ 7.19 - 
7.24 (m, 2H), 6.92 - 6.97 (m, 2H), 3.80 (s, 2H), 3.13 - 3.19 (m, 4H), 1.71 - 1.80 (m, 6H), 1.56 - 
1.64 (m, 2H); 13C NMR (100.6 MHz, CDCl3) δ 151.2, 134.0, 127.8, 116.6, 50.8, 45.9, 25.8, 24.2. 
 
2-Naphthylmethylamine (29k): Lithium aluminum hydride (0.47 g, 12 mmol) and 2-
naphthalenecarbonitrile (0.43 g, 2.8 mmol, 1.0 equiv) in 30 mL diethyl ether; reaction time 40 h; 
compound 29k (0.90 g, 68%) as a colorless solid; m.p 50-52 °C; 1H NMR (400.15 MHz, CDCl3) 
δ 7.82 - 7.91 (m, 3H), 7.76 - 7.81 (m, 1H), 7.44 - 7.53 (m, 3H), 4.07 (s, 2H); 13C NMR (100.6 
MHz, CDCl3) δ 140.7, 133.5, 132.5, 128.2, 127.6, 127.6, 126.0, 125.7, 125.5, 125.0, 46.6. 
 
4-(2-Phenylmethyoxy)benzylamine (29l): Lithium aluminum hydride (0.45 g, 11 mmol) and 4-
[2-benzyloxyethoxy]benzonitrile (0.75 g, 3.0 mmol, 1.0 equiv) in 30 mL diethyl ether; reaction 
time 4 h; compound IO390 (0.68 g, 89%) as a colorless oil; 1H NMR (400.15 MHz, 
METHANOL-d4) δ 7.20 - 7.39 (m, 6H), 6.87 - 6.93 (m, 2H), 4.60 (s, 2H), 4.08 - 4.15 (m, 2H), 
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3.79 - 3.83 (m, 2H), 3.70 (s, 2H); 13C NMR (100.6 MHz, METHANOL-d4) δ 159.3, 139.5, 
136.0, 129.7, 129.4, 128.9, 128.7, 115.7, 74.2, 69.9, 68.6, 46.1. Elemental analysis calculated for 
C16H19NO2; C, 74.68; H, 7.44; N, 5.44, found C, 73.25; H, 7.42; N, 5.32. 
 
4.6: Synthesis of 2,3,4,6-tetra-O-benzyl-D-galactothionolactam  
 Compound 26a (1.66 g, 3.09 mmol, 1.0 equiv) was dissolved in 45 mL of dry benzene 
under nitrogen atmosphere. Lawesson’s reagent (0.87 g, 2.2 mmol, 0.71 equiv) was added and 
the reaction mixture was refluxed for 2 hours. The reaction mixture was cooled to ambient 
temperature and diluted with 200 mL of ethyl acetate. The resulting solution was washed with a 
saturated solution of sodium bicarbonate (50 mL), water (50 mL), brine (50 mL) and dried over 
anhydrous sodium sulfate. The sodium sulfate was filtered off and the resulting solution was 
concentrated under reduced pressure to afford a yellow residue which was purified by column 
chromatography on silica gel (hexane-ethyl acetate; 1/0→6/1→4/1→2/1 v/v) to afford 
compound 27a (1.30 g, 76%) as a yellow oil. 1H NMR (400.15 MHz, DMSO-d6) δ ppm 9.91 (br. 
s., 1 H) 7.20 - 7.45 (m, 22 H) 5.19 (d, J=11.00 Hz, 1 H) 4.81 (d, J=11.37 Hz, 1 H) 4.69 - 4.78 
(m, 2 H) 4.61 (dd, J=18.98, 11.65 Hz, 2 H) 4.44 - 4.56 (m, 2 H) 4.29 (br. s., 1 H) 4.20 (d, J=8.62 
Hz, 1 H) 3.98 (d, J=8.62 Hz, 1 H) 3.85 (br. s., 1 H) 3.69 - 3.77 (m, 1 H) 3.56 - 3.66 (m, 1 H); 13C 
NMR (100 MHz, DMSO-d6) δ ppm 200.7, 138.5, 138.4, 138.3, 137.9, 128.2, 128.2, 128.2, 
128.0, 127.9, 127.7, 127.7, 127.6, 127.5, 127.4, 127.4, 127.3, 81.4, 79.2, 74.3, 73.6, 72.4, 72.0, 
71.3, 67.1, 56.6 




   
The syntheses were performed according to a general protocol described by Rami Kanso and 
Susanne Striegler in Carbohydrate Research, 2011, 346, 897-904. 
Meerwein’s salt was added to a solution of 2,3,4,6-tetra-O-benzyl-D-galactothionolactam in dry 
dichloromethane under nitrogen atmosphere in a 0 °C ice bath and stirred for 2-4 hours. Freshly 
distilled amine was added, and the reaction mixture was warmed to ambient temperature and 
stirred for 16 h – 10 days. The reaction mixture was concentrated under reduced pressure and 
purified by flash column chromatography over deactivated silica gel or basic alumina to afford 
the desired compounds. 
 
2-Benzyloxybenzyl-2,3,4,6-tetra-O-benzyl-D-galactonoamidine (28a): Meerwein’s salt (0.09 
g, 0.5 mmol, 1.5 equiv) and galactothionolactam (0.17 g, 0.31 mmol) in 6 mL of 
dichloromethane; 2-benzyloxybenzylamine (0.13 g, 0.61 mmol, 2.0 equiv); reaction time 42 h; 
silica gel chromatography (cyclohexane/ethyl acetate = 1/0-1/0-10/1-4/1, v/v), basic alumina 
chromatography cyclohexane/ethyl acetate = 8/1-4/1, v/v) compound 28a (0.09 g, 0.1 mmol, 
41%); yellow oil. Rf 0.21 (SiO2, hexane/ethyl acetate = 1/1 v/v); [α]24D +14.9 (c 1.77, CHCl3); 
1H NMR (400.15 MHz, CD2Cl2) δ 7.17 - 7.42 (m, 23H), 6.87 - 6.92 (m, 2H), 5.02 (s, 2H), 4.93 
(d, J = 11.19 Hz, 1H), 4.65 (d, J = 11.19 Hz, 1H), 4.60 (dd, J = 3.12, 11.55 Hz, 2H), 4.56 (s, 2H), 
4.42 - 4.54 (m, 2H), 4.24 - 4.34 (m, 2H), 3.96 (dd, J = 1.93, 9.63 Hz, 1H), 3.58 - 3.78 (m, 3H), 
2.08 (s), 1.28 (s); 13C NMR (100.6 MHz, CD2Cl2) δ 157.2, 156.3, 139.8, 139.4, 139.0, 138.8, 
137.9, 129.8, 129.0, 129.0, 128.9, 128.7, 128.6, 128.5, 128.5, 128.4, 128.3, 128.3, 128.2, 128.1, 
128.0, 127.7, 121.2, 112.2, 82.4, 76.2, 75.2, 74.7, 74.1, 73.8, 72.0, 71.6, 70.4, 60.0, 40.6; vmax 
(FT-IR): 3436, 3024, 2869, 1618, 1491, 1456, 1354, 1228, 1080, 760, 702. HRMS (ESI) 
calculated for C48H48N2O5 [M+H]
+: 733.3636; found 733.3634.  
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3-Benzyloxybenzyl-2,3,4,6-tetra-O-benzyl-D-galactonoamidine (28b): Meerwein’s salt (0.14 
g, 0.73 mmol, 1.5 equiv) and galactothionolactam (0.27 g, 0.49 mmol) in 6 mL of 
dichloromethane; 3-benzyloxybenzylamine (0.21 g, 0.98 mmol, 2.0 equiv); reaction time 182 h; 
basic alumina chromatography (cyclohexane/ethyl acetate = 1/0-10/1-1/2, v/v) compound 28b 
(0.14 g, 0.19 mmol, 40%); yellow oil. Rf 0.08 (SiO2, hexane/ethyl acetate = 2/1 v/v); [α]23D 
+4.23 (c 1.37, CH2Cl2); 
1H NMR (400.15 MHz, CD2Cl2) δ 7.16 - 7.44 (m, 25H), 6.78 - 6.88 (m, 
3H), 5.00 (s, 2H), 4.92 (d, J = 11.00 Hz, 1H), 4.87 (d, J = 11.37 Hz, 1H), 4.83 (d, J = 11.74 Hz, 
1H), 4.60 - 4.68 (m, 3H), 4.50 - 4.57 (m, 3H), 4.20 - 4.35 (m, 3H), 3.98 (dd, J = 1.83, 9.54 Hz, 
1H), 3.55 - 3.78 (m, 3H), 1.28 (s); 13C NMR (100.6 MHz, CD2Cl2) δ 159.5, 156.4, 142.1, 139.7, 
139.4, 138.9, 138.7, 137.8, 129.9, 129.1, 129.0, 129.0, 128.9, 128.8, 128.6, 128.5, 128.4, 128.3, 
128.2, 128.1, 128.1, 128.0, 127.9, 127.4, 120.6, 114.4, 113.9, 82.5, 76.0, 75.3, 74.7, 74.3, 73.8, 
72.0, 71.6, 70.4, 60.1, 45.2. vmax (FT-IR): 3441, 3020, 2874, 1644, 1498, 1462, 1266, 1084, 
1018, 741, 698. HRMS (ESI) calculated for C48H48N2O5 [M+H]
+: 733.3636; found 733.3640.  
4-Benzyloxybenzyl-2,3,4,6-tetra-O-benzyl-D-galactonoamidine (28c): Meerwein’s salt (0.10 
g, 0.53 mmol, 1.5 equiv) and galactothionolactam (0.20 g, 0.36 mmol) in 5 mL of 
dichloromethane; 4-benzyloxybenzylamine (0.15 g, 0.722 mmol, 2.0 equiv); reaction time 34 h; 
silica gel chromatography cyclohexane/ethyl acetate = 10/1-6/1-2/1, v/v) compound 28c (0.15 g, 
0.21 mmol, 57%); yellow oil. Rf 0.23 (SiO2, hexane/ethyl acetate = 1/1 v/v); [α]21D +14.0 (c 
1.04, CHCl3); 
1H NMR (400.15 MHz, CD2Cl2) δ 7.21 - 7.48 (m, 25H), 7.12 (d, J = 8.80 Hz, 2H), 
6.85 - 6.92 (m, 2H), 5.05 (s, 2H), 4.93 (d, J = 11.00 Hz, 1H), 4.80 - 4.88 (m, 2H), 4.59 - 4.68 (m, 
3H), 4.55 (s, 2H), 4.49 (d, J = 9.54 Hz, 1H), 4.28 - 4.34 (m, 1H), 4.12 - 4.25 (m, 2H), 3.97 (dd, J 
= 1.83, 9.72 Hz, 1H), 3.58 - 3.78 (m, 3H), 1.28 (s); 13C NMR (100.6 MHz, CD2Cl2) δ 158.4, 
156.3, 139.7, 139.4, 138.9, 138.7, 137.9, 132.7, 129.5, 129.1, 129.0, 128.9, 128.8, 128.6, 128.5, 
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128.4, 128.3, 128.2, 128.1, 128.0, 115.2, 82.4, 76.0, 75.2, 74.7, 74.2, 73.8, 72.0, 71.6, 70.5, 60.0, 
44.8; νmax (FT-IR) 3067, 3021, 2853, 2021, 1666, 1507, 1460, 1226, 1095, 1012, 740, 703. 
HRMS: calcd for C48H48N2O5 [M+H]
+: 733.3636; found: 733.3627.  
2-Methoxybenzyl-2,3,4,6-tetra-O-benzyl-D-galactonoamidine (28d): Meerwein’s salt (0.07 g, 
0.4 mmol, 1.6 equiv) and galactothionolactam (0.13 g, 0.24 mmol) in 4 mL of dichloromethane; 
2-methoxybenzylamine (0.13 g, 0.61 mmol, 2.0 equiv); reaction time 63 h; silica gel 
chromatography cyclohexane/ethyl acetate = 1/0-10/1-4/1, v/v) compound 28d (0.05 g, 0.08 
mmol, 32%); yellow oil. Rf 0.15 (SiO2, hexane/ethyl acetate = 2/1 v/v); [α]24D +4.68 (c 1.40, 
CH2Cl2); 
1H NMR (400.15 MHz, CD2Cl2) δ 7.20 - 7.49 (m, 22H), 6.86 - 6.96 (m, 2H), 4.97 (d, J 
= 11.00 Hz, 1H), 4.91 (d, J = 11.37 Hz, 1H), 4.86 (d, J = 11.74 Hz, 1H), 4.68 - 4.72 (m, 1H), 
4.63 - 4.68 (m, 2H), 4.61 (s, 2H), 4.33 - 4.38 (m, 2H), 4.01 (dd, J = 1.83, 9.72 Hz, 1H), 3.78 - 
3.86 (m, 1H), 3.66 - 3.76 (m, 5H), 1.29 (s); 13C NMR (100.6 MHz, CD2Cl2) δ 158.2, 156.4, 
139.7, 139.4, 138.9, 138.8, 129.9, 129.0 (2), 128.9, 128.7, 128.5 (2), 128.4, 128.3 (2), 128.2, 
128.1, 128.0, 120.8, 110.8, 82.3, 76.2, 75.2, 74.6, 74.2, 73.8, 72.0, 71.6, 60.0, 55.7, 41.0; vmax 
(FT-IR): 3445, 3033, 2911, 2848, 1640, 1493, 1455, 1238, 1084, 1023, 737, 699. HRMS (ESI) 
calculated for C42H44N2O5 [M+H]
+: 657.3323; found 657.3325.  
 
3-Methoxybenzyl-2,3,4,6-tetra-O-benzyl-D-galactonoamidine (28e): Meerwein’s salt (0.15 g, 
0.77 mmol, 1.5 equiv) and galactothionolactam (0.28 g, 0.51 mmol) in 6 mL of dichloromethane; 
3-methoxybenzylamine (0.15 g, 1.1 mmol, 2.0 equiv); reaction time 14 h; basic alumina 
chromatography cyclohexane/ethyl acetate = 1/0-5/1-2/1, v/v) compound 28e (0.13 g, 0.20 
mmol, 39%); yellow oil. Rf 0.19 (SiO2, hexane/ethyl acetate = 2/1 v/v); [α]24D +9.80 (c 2.05, 
CHCl3) 
1H NMR (400.15 MHz, CD2Cl2) δ 7.24 - 7.45 (m, 21H), 7.15 - 7.24 (m, 1H), 6.71 - 6.84 
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(m, 3H), 4.94 (d, J = 11.00 Hz, 1H), 4.89 (d, J = 11.37 Hz, 1H), 4.84 (d, J = 11.55 Hz, 1H), 4.60 
- 4.69 (m, 3H), 4.54 - 4.59 (m, 2H), 4.51 - 4.55 (m, 1H), 4.32 (s, 1H), 4.27 (d, J = 4.77 Hz, 2H), 
3.99 (dd, J = 1.74, 9.63 Hz, 1H), 3.60 - 3.78 (m, 6H), 1.28 (s); 13C NMR (100.6 MHz, CD2Cl2) δ 
160.4, 156.4, 142.0, 139.7, 139.4, 138.9, 138.7, 129.9, 129.1, 129.0, 128.9, 128.8, 128.6, 128.5, 
128.4, 128.4, 128.2, 128.1, 128.0, 120.3, 113.4, 113.1, 82.5, 76.1, 75.3, 74.7, 74.3, 73.8, 72.0, 
71.7, 60.0, 55.6, 45.3. vmax (FT-IR): 3427, 3018, 2857, 1695, 1628, 1477, 1444, 1268, 1076, 724, 
691. HRMS (ESI) calcd for C42H44N2O5 [M+H]
+: 657.3323; found 657.3333.  
 
4-Butoxybenzyl-2,3,4,6-tetra-O-benzyl-D-galactonoamidine (28f): Meerwein’s salt (0.10 g, 
0.53 mmol, 1.5 equiv) and galactothionolactam (0.20 g, 0.36 mmol) in 3 mL of dichloromethane; 
4-butoxybenzylamine (0.13 g, 0.73 mmol, 2.0 equiv); reaction time 96 h; silica gel 
chromatography hexane/ethyl acetate = 10/1-4/1, v/v); compound 28f (0.10 g, 0.14 mmol, 40%); 
yellow oil. Rf 0.17 (SiO2, hexane/ethyl acetate = 2/1 v/v); [α]24D +10.8 (c 0.88, CHCl3); 1H NMR 
(400.15 MHz, CD2Cl2) δ 7.22 - 7.44 (m, 20H), 7.08 - 7.14 (m, 2H), 6.78 - 6.82 (m, 2H), 4.93 (d, 
J = 11.00 Hz, 1H), 4.84 (dd, J = 10.00, 11.46 Hz, 2H), 4.60 - 4.68 (m, 3H), 4.56 (s, 2H), 4.50 (d, 
J = 9.54 Hz, 1H), 4.31 (t, J = 1.93 Hz, 1H), 4.12 - 4.25 (m, 2H), 3.99 (d, J = 2.02 Hz, 1H), 3.91 - 
3.97 (m, 3H), 3.60 - 3.77 (m, 3H), 1.70 - 1.80 (m, 2H), 1.44 - 1.55 (m, 2H), 0.95 - 1.01 (m, 3H), 
1.28 (s); 13C NMR (100.6 MHz, CD2Cl2) δ 158.9, 156.4, 139.7, 139.4, 138.9, 138.6, 132.0, 
129.5, 129.1, 129.0, 128.9, 128.8, 128.6, 128.5, 128.4, 128.3, 128.2, 128.1, 128.0, 114.9, 82.3, 
76.0, 75.2, 74.6, 74.2, 73.8, 71.9, 71.6, 68.3, 60.0, 44.9, 31.9, 19.8, 14.2. νmax (FT-IR) 3430, 
3037, 2872, 1652, 1502, 1455, 1235, 1092, 739, 675. HRMS: calcd for C45H50N2O5 [M+H]
+: 




   
4-(Piperidin-1-yl)benzyl-2,3,4,6-tetra-O-benzyl-D-galactonoamidine (28g): Meerwein’s salt 
(0.06 g, 0.3 mmol, 1.5 equiv) and galactothionolactam (0.12 g, 0.22 mmol) in 2 mL of 
dichloromethane; 4-(piperidin-1-yl)benzylamine (0.08 g, 0.4 mmol, 1.9 equiv); reaction time 136 
h; silica gel column chromatography (hexane/ethyl acetate = 1/0-10/1-4/1-1/1, v/v) compound 
28g (0.0464 g, 0.0654 mmol, 30%); yellow oil. Rf 0.19 (SiO2, hexane/ethyl acetate = 1/1 v/v); 
[α]21D +5.76 (c 0.63, CHCl3); 1H NMR (400.15 MHz, CD2Cl2) δ 7.16 - 7.44 (m, 19H), 6.99 - 
7.12 (m, 2H), 6.74 - 6.89 (m, 2H), 4.92 (d, J = 11.19 Hz, 1H), 4.84 (d, J = 6.97 Hz, 1H), 4.81 (d, 
J = 7.34 Hz, 1H), 4.59 - 4.66 (m, 3H), 4.54 - 4.57 (m, 2H), 4.46 - 4.51 (m, 1H), 4.30 (t, J = 2.02 
Hz, 1H), 4.08 - 4.22 (m, 2H), 3.97 (dd, J = 1.93, 9.63 Hz, 1H), 3.57 - 3.78 (m, 3H), 3.04 - 3.17 
(m, 4H), 1.69 (td, J = 5.59, 11.19 Hz, 4H), 1.49 - 1.63 (m, 2H), 1.30 (s), 1.03 (s); 13C NMR 
(100.6 MHz, CD2Cl2) δ 156.3, 152.1, 139.8, 139.4, 138.9, 138.7, 130.4, 129.0, 129.0, 128.9, 
128.7, 128.6, 128.5, 128.4, 128.4, 128.3, 128.2, 128.1, 128.0, 116.9, 82.4, 76.1, 75.2, 74.7, 74.1, 
73.8, 72.0, 71.6, 60.0, 51.3, 46.9, 45.0, 26.5, 24.9; vmax (FT-IR): 3021, 2933, 2854, 1659, 1510, 




2-(3-Indolyl)ethyl-2,3,4,6-tetra-O-benzyl-D-galactonoamdine (28h): Meerwein’s salt (0.15 g, 
0.81 mmol, 1.5 equiv) and galactothionolactam (0.30 g, 0.54 mmol) in 4 mL of dichloromethane; 
2-(3-indolyl)ethylamine (0.18 g, 1.1 mmol, 2.1 equiv); reaction time 35 h; silica gel column 
chromatography (cyclohexane/ethyl acetate = 1/0-10/1-4/1, v/v) compound 28h (0.19 g, 0.28 
mmol, 52%); colorless foam. Rf 0.09 (SiO2, hexane/ethyl acetate = 2/1 v/v); [α]18D +35.6 (c 0.71, 
CHCl3); 
1H NMR (400.15 MHz, CD2Cl2) δ 7.95 (br. s., 1H), 7.58 (d, J = 7.89 Hz, 1H), 7.21 - 
7.45 (m, 18H), 7.09 - 7.18 (m, 3H), 7.01 - 7.07 (m, 1H), 6.86 (d, J = 2.02 Hz, 1H), 4.88 - 4.96 
 
39 
   
(m, 1H), 4.80 (dd, J = 5.78, 11.46 Hz, 2H), 4.62 - 4.66 (m, 1H), 4.57 - 4.62 (m, 1H), 4.56 (s, 
2H), 4.51 (d, J = 11.19 Hz, 1H), 4.42 (d, J = 9.17 Hz, 1H), 4.24 - 4.33 (m, 1H), 3.93 (dd, J = 
1.83, 9.72 Hz, 1H), 3.76 (dd, J = 3.94, 7.06 Hz, 1H), 3.59 - 3.72 (m, 2H), 3.43 (t, J = 6.69 Hz, 
2H), 2.89 (t, J = 6.88 Hz, 2H) 1.28 (s, 1H); 13C NMR (100.6 MHz, CD2Cl2) δ 156.6, 139.8, 
139.3, 138.9, 138.7, 136.9, 129.0, 128.9, 128.9, 128.8, 128.6, 128.6, 128.4, 128.3, 128.2, 128.1, 
128.0, 122.7, 122.3, 119.6, 119.3, 113.8, 111.6, 82.3, 76.2, 75.3, 74.6, 74.2, 73.8, 71.9, 71.6, 
60.0, 41.4, 25.2. vmax (FT-IR): 3062, 2923, 2838, 1630, 1506, 1444, 1367, 1090, 728, 697. 
HRMS (ESI) calculated for C44H45N3O4 [M+H]
+: 680.3483; found 680.3482.  
 
2,2’Diphenylethyl-2,3,4,6-tetra-O-benzyl-D-galactonoamidine (28i): Meerwein’s salt (0.08 g, 
0.4 mmol, 1.6 equiv) and galactothionolactam (0.15 g, 0.27 mmol) in 3 mL of dichloromethane; 
2,2’-diphenylethylamine (0.11 g, 0.56 mmol, 2.1 equiv); reaction time 87 h; silica gel 
chromatography (cyclohexane/ethyl acetate = 1/0-10/1- 4/1, v/v) compound 28i (0.11 g, 0.15 
mmol, 57%); yellow oil. Rf 0.39 (SiO2, hexane/ethyl acetate = 1/1 v/v); [α]24D +22.9 (c 1.17, 
CHCl3); 
1H NMR (400.15 MHz, CD2Cl2) δ 7.16 - 7.47 (m, 26H), 6.95 (dd, J = 1.56, 7.61 Hz, 
2H), 4.91 (d, J = 11.00 Hz, 1H), 4.80 (d, J = 11.74 Hz, 1H), 4.70 (d, J = 11.00 Hz, 1H), 4.59 - 
4.65 (m, 2H), 4.57 (s, 2H), 4.41 - 4.48 (m, 1H), 4.35 (d, J = 9.54 Hz, 1H), 4.29 (t, J = 1.93 Hz, 
1H), 4.12 - 4.22 (m, 1H), 3.91 (dd, J = 1.83, 9.72 Hz, 1H), 3.59 - 3.82 (m, 4H), 1.28 (s); 13C 
NMR (100.6 MHz, CD2Cl2) δ 156.3, 143.4, 143.2, 139.8, 139.4, 138.9, 138.4, 129.2, 129.1, 
129.0, 128.9, 128.7 (2), 128.6, 128.5 (2), 128.4, 128.3 (2), 128.2, 128.1, 128.0, 127.1, 127.1, 
82.4, 75.8, 75.2, 74.6, 74.2, 73.8, 72.0, 71.6, 60.0, 50.7, 45.6. vmax (FT-IR): 3428, 3027, 2926, 
2857, 1650, 1487, 1463, 1084, 1022, 728, 704. HRMS calcd for C48H48N2O4 [M+H]
+: 717.3687; 
found 717.3699.  
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2-Naphthylmethyl-2,3,4,6-tetra-O-benzyl-D-galactonoamidine (28j): Meerwein’s salt (0.08 g, 
0.4 mmol, 1.5 equiv) and galactothionolactam (0.16 g, 0.29 mmol) in 2 mL of dichloromethane; 
2-napthalenemethanamine (0.09 g, 0.6 mmol, 2.0 equiv); reaction time 89 h; silica gel column 
chromatography (cyclohexane/ethyl acetate = 1/0-10/1-4/1, v/v) compound 28j (0.0633 g, 0.0935 
mmol, 32%); yellow oil. Rf 0.13 (SiO2, hexane/ethyl acetate = 2/1 v/v); [α]24D +13.2 (c 1.03, 
CHCl3) 
1H NMR (400.15 MHz, CD2Cl2) δ 7.72 - 7.87 (m, 4H), 7.65 (s, 1H), 7.40 - 7.50 (m, 5H), 
7.20 - 7.40 (m, 19H), 4.95 (d, J = 11.19 Hz, 1H), 4.89 (d, J = 11.37 Hz, 1H), 4.84 (d, J = 11.74 
Hz, 1H), 4.61 - 4.70 (m, 3H), 4.52 - 4.59 (m, 3H), 4.44 - 4.49 (m, 2H), 4.30 - 4.36 (m, 1H), 4.01 
(dd, J = 1.83, 9.54 Hz, 1H), 3.70 - 3.78 (m, 2H), 3.61 - 3.68 (m, 1H), 1.28 (s); 13C NMR (100.6 
MHz, CD2Cl2) δ 156.5, 139.8, 139.4, 138.9, 134.0, 133.2, 129.1, 129.0, 128.9, 128.8, 128.6, 
128.5, 128.5, 128.4, 128.4, 128.2, 128.1, 128.1, 128.0, 126.7, 126.5, 126.4, 126.1, 82.4, 76.1, 
75.3, 74.7, 74.3, 73.8, 71.9, 71.7, 60.0, 45.5. vmax (FT-IR): 3439, 3067, 3010, 2914, 2858, 1638, 
1500, 1444, 1096, 732, 684. HRMS (ESI) calculated for C45H44N2O5 [M+H]
+: 677.3374; found 
677.3372.  
 
4-Phenylbenzyl-2,3,4,6-tetra-O-benzyl-D-galactonoamidine (28k): Meerwein’s salt (0.11 g, 
0.58 mmol, 1.5 equiv) and galactothionolactam (0.21 g, 0.38 mmol) in 3 mL of acetonitrile; 4-
phenylbenzylamine (0.17 g, 0.93 mmol, 2.4 equiv); reaction time 115 h; basic alumina column 
chromatography (hexane/ethyl acetate = 1/0-4/1-1/1, v/v) compound 28k (0.08 g, 0.1 mmol, 
30%); yellow oil. Rf 0.10 (SiO2, hexane/ethyl acetate = 2/1 v/v); [α]18D +13.4 (c 0.62, CHCl3); 
1H NMR (400.15 MHz, CD2Cl2) δ 7.58 - 7.63 (m, 2H), 7.51 - 7.55 (m, 2H), 7.45 - 7.48 (m, 2H), 
7.41 - 7.44 (m, 3H), 7.25 - 7.40 (m, 21H), 4.95 (d, J = 11.00 Hz, 1H), 4.90 (d, J = 11.37 Hz, 1H), 
4.85 (d, J = 11.55 Hz, 1H), 4.68 (d, J = 2.57 Hz, 1H), 4.62 - 4.67 (m, 2H), 4.53 - 4.58 (m, 3H), 
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4.30 - 4.36 (m, 3H), 4.00 (dd, J = 1.83, 9.54 Hz, 1H), 3.69 - 3.78 (m, 2H), 3.61 - 3.68 (m, 1H), 
1.28 (s); 13C NMR (100.6 MHz, CD2Cl2) δ 156.4, 141.4, 140.3, 139.7, 139.5, 139.4, 138.9, 
138.7, 129.3, 129.1, 129.0, 128.9, 128.8, 128.7, 128.6, 128.5, 128.5, 128.4, 128.4, 128.2, 128.1, 
128.0, 127.8, 127.6, 127.5, 82.4, 76.0, 75.3, 74.6, 74.4, 73.8, 71.9, 71.7, 60.0, 45.0;. vmax (FT-
IR): 3449, 3011, 2869, 1658, 1490, 1335, 1090, 755, 716. HRMS (ESI) calculated for 
C47H47N2O4 [M+H]
+: 703.3536; found 703.3530.  
 
4-(4’-Methylphenyl)benzyl-2,3,4,6-tetra-O-benzyl-D-galactonoamidine (28l): Meerwein’s 
salt (0.11 g, 0.579 mmol, 1.5 equiv) and galactothionolactam (0.22 g, 0.40 mmol) in 3 mL of 
acetonitrile; 4-(4’-methylphenyl)benzylamine (0.17 g, 0.86 mmol, 2.2 equiv); reaction time 115 
h; basic alumina column chromatography (hexane/ethyl acetate = 8/1-4/1, v/v) compound 28l 
(0.10 g, 0.14 mmol, 35%); yellow oil. Rf 0.21 (SiO2, hexane/ethyl acetate = 1/1 v/v); [α]20D 
+7.05 (c 0.55, CHCl3) 
1H NMR (400.15 MHz, CD2Cl2) δ 7.46 - 7.52 (m, 4H), 7.23 - 7.43 (m, 
24H), 4.94 (d, J = 11.00 Hz, 1H), 4.88 (d, J = 11.37 Hz, 1H), 4.84 (d, J = 11.74 Hz, 1H), 4.64 
(dd, J = 9.26, 11.10 Hz, 3H), 4.51 - 4.57 (m, 3H), 4.28 - 4.35 (m, 2H), 3.99 (dd, J = 1.83, 9.72 
Hz, 1H), 3.68 - 3.76 (m, 2H), 3.57 - 3.67 (m, 1H), 2.32 - 2.45 (m, 3H); 13C NMR (100.6 MHz, 
CD2Cl2) δ 156.3, 140.2, 139.7, 139.4, 139.2, 138.9, 138.7, 138.5, 137.7, 130.0, 129.2, 129.1, 
129.0, 128.9, 128.8, 128.7, 128.6, 128.5, 128.4, 128.4, 128.3, 128.3, 128.2, 128.1, 128.0, 127.3, 
127.3, 82.5, 76.1, 75.3, 74.7, 74.3, 73.8, 72.0, 71.7, 60.1, 45.0, 21.4; vmax (FT-IR): 3435, 3031, 
2863, 2613, 1649, 1496, 1450, 1208, 1090, 728, 696, 639. HRMS (ESI) calculated for 
C48H49N2O4 [M+H]




   
4-(4’-Fluorophenyl)benzyl-2,3,4,6-tetra-O-benzyl-D-galactonoamidine (28m): Meerwein’s 
salt (0.08 g, 0.4 mmol, 1.7 equiv) and galactothionolactam (0.14 g, 0.25 mmol) in 2 mL of 
acetonitrile; 4-(4’-fluorophenyl)benzylamine (0.10 g, 0.50 mmol, 2.0 equiv); reaction time 23 h; 
basic alumina column chromatography (hexane/ethyl acetate = 1/0-10/1-4/1, v/v) compound 
28m (0.0334 g, 0.0464 mmol, 18%); yellow oil. Rf 0.10 (SiO2, hexane/ethyl acetate = 2/1 v/v); 
[α]20D +12.4 (c 0.75, CHCl3); 1H NMR (400.15 MHz,CD2Cl2) δ 7.55 - 7.60 (m, 2H), 7.46 - 7.50 
(m, 2H), 7.41 - 7.45 (m, 2H), 7.26 - 7.40 (m, 20H), 7.12 - 7.19 (m, 2H), 4.95 (d, J = 11.00 Hz, 
1H), 4.91 (d, J = 11.37 Hz, 1H), 4.85 (d, J = 11.74 Hz, 1H), 4.62 - 4.69 (m, 4H), 4.52 - 4.60 (m, 
4H), 4.28 - 4.39 (m, 4H), 4.01 (dd, J = 1.83, 9.54 Hz, 1H), 3.68 - 3.77 (m, 2H), 3.61 - 3.68 (m, 
1H); 13C NMR (100.6 MHz, CD2Cl2) δ 163.0 (d, J = 245.4 Hz), 156.3, 139.7, 139.5, 139.4, 
139.2, 138.9, 138.7, 137.7 (d, J = 3.2 Hz), 129.2, 129.1, 129.0, 128.9, 128.8, 128.7, 128.5, 128.4, 
128.4, 128.3, 128.2, 128.2, 128.1 (d, J = 4.4 Hz), 127.4, 116.1 (d, J = 21.5 Hz), 82.5, 76.1, 75.3, 
74.7, 74.4, 73.8, 71.9, 71.7, 60.0, 45.0. vmax (FT-IR): 3420, 3034, 2859, 1646, 1498, 1222, 1084, 
809, 735, 698. HRMS (ESI) calculated for C47H46N2O4 [M+H]
+: 721.3442; found 721.3443.  
 
4-(2-Phenylmethoxy)benzyl-2,3,4,6-tetra-O-benzyl-D-galactonoamidine (28n) : Meerwein’s 
salt (0.07 g, 0.4 mmol, 1.5 equiv) and galactothionolactam (0.14 g, 0.25 mmol) in 2 mL of 
acetonitrile; 4-(2-phenylmethyoxy)benzylamine (0.10 g, 0.39 mmol, 2.1 equiv); reaction time 94 
h; silica gel column chromatography (hexane/ethyl acetate = 1/0-4/1-1/2, v/v) compound 28n 
(0.0436 g, 0.0560 mmol, 22%); yellowish oil. Rf 0.07 (SiO2, hexane/ethyl acetate = 2/1 v/v); 
[α]21D +6.80 (c 0.68, CHCl3); 1H NMR (400.15 MHz, CD2Cl2) δ 7.21 - 7.43 (m, 25H), 7.09 - 
7.14 (m, 2H), 6.80 - 6.86 (m, 2H), 4.93 (d, J = 11.00 Hz, 1H), 4.80 - 4.88 (m, 2H), 4.63 - 4.67 
(m, 2H), 4.59 - 4.62 (m, 3H), 4.56 (s, 2H), 4.50 (d, J = 9.72 Hz, 1H), 4.31 (t, J = 1.93 Hz, 1H), 
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4.16 - 4.25 (m, 2H), 4.10 - 4.15 (m, 2H), 3.97 (dd, J = 1.83, 9.72 Hz, 1H), 3.80 - 3.84 (m, 2H), 
3.59 - 3.76 (m, 3H); 13C NMR (100.6 MHz, CD2Cl2) δ 158.5, 156.3, 139.7, 139.4, 139.0, 138.9, 
138.7, 132.6, 129.5, 129.1, 129.0, 128.9, 128.9, 128.8, 128.6, 128.5, 128.4, 128.3, 128.3, 128.2, 
128.1, 128.1, 128.0, 115.0, 82.4, 76.0, 75.2, 74.7, 74.2, 73.8, 73.8, 72.0, 71.6, 69.3, 68.1, 60.0, 
44.8. vmax (FT-IR): 3439, 3043, 2915, 2838, 1645, 1503, 1461, 1240, 1091, 745, 697. HRMS 
(ESI) calculated for C50H53N2O6 [M+H]
+: 777.3904; found 777.3891.  
 
4-(Cyclohexylmethoxy)benzyl-2,3,4,6-tetra-O-benzyl-D-galactonoamidine (28o): 
Meerwein’s salt (0.11 g, 0.60 mmol, 1.5 equiv) and galactothionolactam (0.22 g, 0.40 mmol) in 3 
mL of acetonitrile; 4-(cyclohexyl methoxy)benzylamine (0.17 g, 0.78 mmol, 2.0 equiv); reaction 
time 23 h; basic alumina column chromatography (hexane/ethyl acetate = 1/0-10/1-4/1 v/v) 
compound 28o (0.0912 g, 0.123 mmol, 31%); yellow oil. Rf 0.26 (SiO2, hexane/ethyl acetate = 
1/1 v/v); [α]20D +8.50 (c 0.66, CHCl3); 1H NMR (400.15 MHz, CD2Cl2) δ 7.20 - 7.46 (m, 24H), 
7.08 - 7.16 (m, 2H), 6.73 - 6.86 (m, 2H), 4.94 (d, J = 11.00 Hz, 2H), 4.85 (dd, J = 8.71, 11.46 
Hz, 2H), 4.60 - 4.68 (m, 4H), 4.54 - 4.60 (m, 3H), 4.48 - 4.53 (m, 1H), 4.32 (t, J = 1.93 Hz, 1H), 
4.14 - 4.25 (m, 2H), 3.98 (dd, J = 1.83, 9.72 Hz, 1H), 3.59 - 3.79 (m, 7H), 1.83 - 1.94 (m, 3H), 
1.66 - 1.82 (m, 6H), 1.19 - 1.40 (m, 5H), 1.00 - 1.14 (m, 3H); 13C NMR (100.6 MHz, CD2Cl2) δ 
159.0, 156.2, 139.8, 139.4, 138.9, 138.7, 132.1, 129.4, 129.1, 129.0, 128.9, 128.8, 128.6, 128.5, 
128.4, 128.3, 128.2, 128.1, 128.0, 114.9, 82.4, 76.1, 75.2, 74.7, 74.2, 74.1, 73.8, 72.0, 71.6, 60.1, 
44.9, 38.3, 30.5, 27.2, 26.4; vmax (FT -IR): 3028, 2916, 2838, 1634, 1498, 1239, 1081, 733. 
HRMS (ESI) calculated for C48H55N2O5 [M+H]




   
O-Benzylethanol-2,3,4,6-tetra-O-benzyl-D-galactonoamidine (28p): Meerwein’s salt (0.07 g, 
0.4 mmol, 1.6 equiv) and galactothionolactam (0.13 g, 0.24 mmol) in 2 mL of acetonitrile; O-
benzylethanolamine (0.07 g, 0.5 mmol, 2.0 equiv); reaction time 97 h; silica gel column 
chromatography (hexane/ethyl acetate = 4/1-1/1, v/v) compound 28p (0.0436 g, 0.0650 mmol, 
22%); yellow oil. Rf 0.21 (SiO2, hexane/ethyl acetate = 1/1 v/v); [α]21D +32.1 (c 0.58, CHCl3); 
1H NMR (400.15 MHz, CD2Cl2) δ 7.02 - 7.53 (m, 25H), 4.92 (d, J = 11.00 Hz, 1H), 4.87 (d, J = 
11.19 Hz, 1H), 4.82 (d, J = 11.74 Hz, 1H), 4.63 (td, J = 5.43, 10.96 Hz, 3H), 4.53 - 4.57 (m, 2H), 
4.45 - 4.51 (m, 3H), 4.29 (t, J = 2.02 Hz, 1H), 3.95 (dd, J = 1.93, 9.63 Hz, 1H), 3.58 - 3.73 (m, 
3H), 3.46 - 3.57 (m, 2H), 3.20 - 3.43 (m, 2H); 13C NMR (100.6 MHz, CD2Cl2) δ 156.5, 139.7, 
139.4, 139.1, 138.9, 138.7, 129.0, 129.0, 128.9, 128.8, 128.7, 128.6, 128.5, 128.4, 128.3, 128.2, 
128.1, 128.1, 128.0, 82.3, 76.0, 75.2, 74.7, 74.2, 73.8, 73.4, 71.9, 71.6, 69.4, 60.0, 41.1; . vmax 
(FT-IR): 3024, 2947, 2862, 1646, 1499, 1464, 1361, 1087, 736, 703. HRMS (ESI) calculated for 
C43H47N2O5 [M+H]
+: 671.3485; found 671.3470.  
4.8: General procedure for the synthesis of galactonoamidines  
The perbenzylated galactonoamidines were suspended with palladium (30 wt % on activated 
carbon) and 5/1 v/v mixture of ethanol and trifluoroacetic acid and stirred under hydrogen 
atmosphere at ambient temperature. After 16-24 h, the mixture was filtered through a pad of 
Celite. The pad was rinsed with 2 mL of ethanol three times. The combined filtrated were 
concentrated under reduced pressure to about 2 mL. Centrifuged at 8500 rpm for 10-15 minutes, 
concentrated to form a residue which was lyophilized to obtain the desired amidines. 
2-Hydroxybenzyl-D-galactonoamidine (16k): Compound 28a (0.0588 g, 0.0802 mmol), Pd/C 
(0.05 g) in 0.8 mL of trifluoroacetic acid and 4 mL of ethanol; reaction time 40 h; ethanol 
amount for rinsing 2 mL each; compound 16k (0.0221 g, 0.0783 mmol, 98%); yellow foam. Rf = 
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0.23 (SiO2, ethyl acetate/methanol = 5/1 v/v); [α]23D +25.0 (c 0.68, H2O) 1H NMR (400.15 MHz, 
D2O + MeOD) δ 7.27 - 7.37 (m, 2H), 6.94 - 7.04 (m, 2H), 4.52 - 4.62 (m, 3H), 4.29 (s, 1H), 3.94 
(dd, J = 2.38, 10.09 Hz, 1H), 3.86 (d, J = 5.50 Hz, 1H), 3.74 - 3.82 (m, 2H); 13C NMR (100.6 
MHz, D2O) δ 164.7, 154.5, 131.6, 131.4, 122.0, 121.7, 116.5, 71.6, 68.0, 67.3, 61.4, 58.4, 41.1. 
vmax (FT-IR): 3241, 2951, 1668, 1457, 1185, 1141, 842, 807, 763, 720. HRMS (ESI) calculated 
for C13H18N2O5 [M+H]
+: 283.1288; found 283.1293.  
 
3-Hydroxybenzyl-D-galactonoamidine (16l): Compound 28b (0.0914 g, 0.125 mmol), Pd/C 
(0.10 g) in 1.5 mL of trifluoroacetic acid and 7.5 mL of ethanol; reaction time 60 h; ethanol 
amount for rinsing 2 mL each; compound 16l (0.0351 g, 0.125 mmol, 100%); yellow foam. Rf = 
0.15 (SiO2, ethyl acetate/methanol = 10/1 v/v); [α]21D +21.4 (c 0.92, H2O); 1H NMR (400.15 
MHz, D2O) δ 7.33 (t, J = 7.89 Hz, 1H), 6.81 - 6.96 (m, 3H), 4.65 - 4.70 (m, 1H), 4.61 (d, J = 
4.40 Hz, 2H), 4.31 (t, J = 2.20 Hz, 1H), 4.01 (dd, J = 2.29, 10.18 Hz, 1H), 3.69 - 3.88 (m, 3H); 
13C NMR (100.6 MHz, D2O+MeOD) δ 165.0, 157.4, 136.6, 131.6, 120.4, 116.1, 115.1, 71.3, 
68.0, 67.4, 61.0, 58.3, 45.9. vmax (FT-IR): 3243, 2934, 1645, 1451, 1193, 1141, 858, 793, 716. 
HRMS (ESI) calculated for C13H18N2O5 [M+H]
+: 283.1288; found 283.1293.  
 
4-Hydroxybenzyl-D-galactonoamidine (16m): Compound 28c (0.1017 g, 0.1388 mmol), Pd/C 
(0.11 g) in 1 mL of trifluoroacetic acid and 5 mL of ethanol; reaction time 38 h; ethanol amount 
for rinsing 2 mL each; compound 16m (0.0370 g, 0.131 mmol, 94%); colorless foam. Rf = 0.29 
(SiO2, ethyl acetate/methanol = 5/1 v/v); [α]24D +17.4 (c 1.00, H2O); 1H NMR (400.15 MHz, 
D2O) δ 7.27 (d, J = 8.44 Hz, 2H), 6.79 - 7.05 (m, 2H), 4.64 (d, J = 10.27 Hz, 1H), 4.57 (d, J = 
2.57 Hz, 1H), 4.32 (t, J = 2.20 Hz, 1H), 4.00 (dd, J = 2.38, 10.09 Hz, 1H), 3.71 - 3.88 (m, 3H); 
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13C NMR (100.5 MHz, D2O) δ 165.6, 157.2, 130.9, 127.2, 117.7, 72.2, 68.6, 68.0, 61.7, 58.9, 
46.4. vmax (FT-IR): 3255, 1655, 1130, 799, 722, 593. HRMS calcd for C13H18N2O5 [M+H]
+: 
283.1288; found 283.1285.  
 
Ethanol-D-galactonoamidine (16n): Compound 28p (0.1008 g, 0.1736 mmol), Pd/C (0.11 g) in 
2.5 mL of trifluoroacetic acid and 5 mL of ethanol; reaction time 24 h; ethanol amount for 
rinsing 2 mL each; compound 16n (0.0386 g, 0.175 mmol, 99%); colorless foam. Rf = 0.61 
(SiO2, ethyl acetate/methanol = 5/1 v/v); [α]23D +19.1 (c 0.96, H2O); 1H NMR (400.15 MHz, 
D2O) δ 4.63 (d, J = 10.27 Hz, 1H), 4.29 - 4.36 (m, 1H), 4.00 (dd, J = 2.38, 10.27 Hz, 1H), 3.78 - 
3.90 (m, 6H), 3.53 - 3.61 (m, 2H); 13C NMR (100.6 MHz, D2O) δ 167.0, 72.2, 68.6, 68.1, 61.8, 
61.3, 58.8, 46.2. vmax (FT-IR): 3350, 1668, 1202, 1169. HRMS (ESI) calcd for C8H16N2O5 
[M+H]+: 221.1132; found 221.1128. 
 
2-Methoxybenzyl-D-galactonoamidine (16o): Compound 28d (0.0543 g, 0.0827 mmol), Pd/C 
(0.05 g) in 0.8 mL of trifluoroacetic acid and 4 mL of ethanol; reaction time 40 h; ethanol 
amount for rinsing 2 mL each; compound 16o (0.0245 g, 0.0827 mmol, quantitative); yellow 
foam. Rf = 0.19 (SiO2, ethyl acetate/methanol = 5/1 v/v); [α]25D +28.8 (c 0.54, H2O); 1H NMR 
(400.15 MHz, D2O) δ 7.33 - 7.51 (m, 2H), 7.02 - 7.18 (m, 2H), 4.53 - 4.66 (m, 3H), 4.30 (br. s., 
1H), 3.85 - 3.99 (m, 5H), 3.79 (br. s., 2H); 13C NMR (100.6 MHz, D2O) δ 164.2, 157.6, 131.3, 
130.8, 122.7, 122.1, 112.4, 71.3, 67.8, 67.1, 61.2, 58.2, 56.6, 41.1; vmax (FT-IR): 3286, 2921, 
1662, 1446, 1197, 1139, 799, 790, 716, 509. HRMS (ESI) calculated for C14H20N2O5 [M+H]
+: 




   
3-Methoxybenzyl-D-galactonoamidine (16p): Compound 28e (0.1434 g, 0.2183 mmol), Pd/C 
(0.15 g) in 1mL of trifluoroacetic acid and 5 mL of ethanol; reaction time 36 h; ethanol amount 
for rinsing 2 mL each; compound 16p (0.0647 g, 0.218 mmol, quantitative); yellow foam. Rf = 
0.16 (SiO2, ethyl acetate/methanol = 10/1 v/v); [α]24D +21.8 (c 0.72, H2O); 1H NMR (400.15 
MHz, D2O) δ 7.41 (t, J = 7.89 Hz, 1H), 6.95 - 7.04 (m, 3H), 4.62 - 4.70 (m, 3H), 4.32 (br. s., 
1H), 4.01 (dd, J = 1.93, 10.00 Hz, 1H), 3.67 - 3.88 (m, 6H); 13C NMR (100.6 MHz, D2O) δ 
165.9, 161.0, 137.1, 132.1, 121.5, 115.5, 114.6, 72.2, 68.6, 68.1, 61.6, 59.0, 57.0, 46.7; vmax (FT-
IR): 3243,1666, 1438, 1200, 1151, 849, 800, 719. HRMS (ESI) calcd for C14H20N2O5 [M+H]
+: 
297.1445; found 297.1452.  
 
4-Butoxybenzyl-D-galactonoamidine (16q): Compound 28f (0.0905 g, 0.129 mmol), Pd/C 
(0.05 g) in 0.5 mL of trifluoroacetic acid and 2.mL of ethanol; reaction time 15 h; ethanol 
amount for rinsing 2 mL each; compound 16q (0.0437 g, 0.129 mmol, 99%); yellow foam. Rf = 
0.38 (SiO2, ethyl acetate/methanol = 5/1 v/v); [α]24D +26.7 (c 0.82, H2O); 1H NMR (400.15 
MHz, D2O) δ 7.31 (d, J = 8.25 Hz, 2H), 7.01 (d, J = 8.44 Hz, 2H), 4.64 (d, J = 10.09 Hz, 1H), 
4.57 (br. s., 2H), 4.30 (br. s., 1H), 4.06 (t, J = 6.42 Hz, 2H), 3.99 (d, J = 9.35 Hz, 1H), 3.65 - 3.89 
(m, 3H), 1.65 - 1.82 (m, 2H), 1.43 (qd, J = 7.31, 14.58 Hz, 2H), 0.93 (t, J = 7.34 Hz, 3H); 13C 
NMR (100.6 MHz, D2O+MeOD) δ 165.6, 159.9, 130.7, 127.9, 116.9, 72.2, 70.1, 68.6, 68.0, 
61.6, 58.9, 46.3, 32.0, 20.2, 14.6. vmax (FT-IR): 3350, 1660, 1210, 1113. HRMS (ESI) calcd for 
C17H26N2O5 [M+H]
+: 339.1914; found 339.1909.  
 
2,2’-Diphenylethyl-D-galactonoamidine (16r): Compound 28i (0.1006 g, 0.1403 mmol), Pd/C 
(0.10 g) in 1.4 mL of trifluoroacetic acid and 7.mL of ethanol; reaction time 18 h; ethanol 
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amount for rinsing 2 mL each; compound 16r (0.0483 g, 0.136 mmol, 97%); yellow foam. Rf = 
0.63 (SiO2, ethyl acetate/methanol = 10/1 v/v); [α]24D +21.3 (c 0.88, MeOH); 1H NMR (400.15 
MHz, MeOD) δ 7.55 - 7.71 (m, 1H), 7.16 - 7.35 (m, 5H), 4.28 - 4.41 (m, 1H), 4.05 - 4.13 (m, 
1H), 3.97 - 4.04 (m, 1H), 3.63 - 3.73 (m, 1H), 3.56 - 3.62 (m, 1H), 3.24 - 3.40 (m, 2H), 2.78 - 
3.02 (m, 3H); 13C NMR (100.6 MHz, MeOD) δ 166.4, 142.5, 142.3, 129.9, 129.8, 129.3, 129.0, 
128.3, 128.2, 72.4, 68.5, 67.8, 61.4, 59.4, 50.9, 47.1. vmax (FT-IR): 3363, 2863, 1663, 1438, 
1196, 1116, 834, 801, 704. HRMS (ESI) calcd for C20H24N2O4 [M+H]
+: 357.1809; found 
357.1801.  
 
4-Phenylbenzyl-D-galactonoaomamidine (16s): Compound 28k (0.08 g, 0.1 mmol), Pd/C (0.08 
g) in 1 mL of trifluoroacetic acid and 5 mL of ethanol; reaction time 41 h; ethanol amount for 
rinsing 2 mL each; compound 16s (0.0390 g, 0.114 mmol, quantitative); colorless foam. Rf = 
0.07 (SiO2, ethyl acetate/methanol = 5/1 v/v); [α]D
20+25.4 (c 0.528, MeOH); 1H NMR (400.15 
MHz, METHANOL-d4) δ 7.66 (d, J = 8.25 Hz, 2H), 7.57 - 7.63 (m, 2H), 7.39 - 7.47 (m, 4H), 
7.31 - 7.36 (m, 1H), 7.24 (s, 1H), 4.65 - 4.69 (m, 2H), 4.55 - 4.64 (m, 1H), 4.20 (t, J = 2.48 Hz, 
1H), 3.86 (dd, J = 2.29, 9.63 Hz, 1H), 3.78 (t, J = 6.51 Hz, 2H), 3.69 (dd, J = 2.66, 6.33 Hz, 1H), 
2.37 (s); 13C NMR (100.6 MHz, METHANOL-d4) δ 166.7, 142.6, 141.6, 134.8, 129.9, 128.9, 
128.6, 128.6, 127.9, 72.7, 68.7, 68.4, 61.4, 59.5, 45.9. vmax (FT-IR): 3256, 2921, 1670, 1438, 
1206, 1128. HRMS (ESI) m/z calcd for C19H23N2O4 [M+H]
+: 343.1658 found 343.1657. 
 
2-(Octahydro-1H-indol-3-yl)ethyl-D-galactonoamidine (16t) Compound 28h (60.70 mg, 
0.0893 mmol), Pd/C (0.06 g) in 2.0 mL of trifluoroacetic acid and 6.0 mL of ethanol; reaction 
time 61 h; ethanol amount for rinsing 2 mL each; compound 16t (0.0446 g, 0.140 mmol, 156%); 
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colorless foam. Rf = 0.26 (SiO2, dichloromethane/methanol = 25/1 v/v); 
1H NMR (400.15 MHz, 
D2O) δ 4.63 (d, J = 10.09 Hz, 1H), 4.38 (br. s., 1H), 4.02 (d, J = 10.27 Hz, 1H), 3.79 - 3.94 (m, 
3H), 3.47 (d, J = 6.60 Hz, 3H), 2.94 - 3.18 (m, 1H), 2.21 - 2.60 (m, 1H), 1.70 (d, J = 10.82 Hz, 
8H), 1.11 - 1.53 (m, 4H); 13C NMR (100.6 MHz, D2O) δ 164.1, 163.2, 162.8, 117.9, 115.0, 70.6, 
67.2, 66.4, 63.7, 60.1, 58.6, 58.5, 57.4, 47.2, 42.0, 40.5, 40.4, 39.2, 38.7, 38.5, 36.3, 36.1, 30.3, 
29.2, 27.9, 25.0, 24.5, 24.0, 23.9, 22.8, 21.8, 20.5, 20.3, 19.1; LC-MS calculated for C16H29N3O4 
[M+H]+: 328.4; found 328.3 and 356.3 
 
N-4(4’-Methylphenyl)benzyl-D-galactonoamidine (16u): Compound 28k (0.05 g, 0.07 mmol); 
Pd/C (0.05 g) in 1 mL of trifluoroacetic acid and 5 mL ethanol; reaction time 72 h; ethanol 
amount for rinsing 2 mL each; compound 16u (0.0532 g, 0.155 mmol, 222%); beige foam. Rf = 
0.23 (SiO2, ethyl acetate/methanol = 5/1 v/v). 
 
N-4(4’-Fluorophenyl)benzyl-D-galactonoamidine (16v): Compound 28m (0.0334 g, 0.0463 
mmol); Pd/C (0.03 g) in 0.5 mL of trifluoroacetic acid and 2.5 mL ethanol; reaction time 37 h; 
ethanol amount for rinsing 2 mL each; compound 16v (0.0349 g, 0.0968 mmol, 209%); 
yellowish foam. 
N-2-Napthylmethyl-D-galactonoamidine (16w): Compound 28j (0.05 g, 0.074 mmol); Pd/C 
(0.05 g) in 0.5 mL of trifluoroacetic acid and 5 mL ethanol; reaction time 69 h; ethanol amount 
for rinsing 2 mL each; compound IO406 (0.0381 g, 0.1216 mmol, 164%); yellowish foam. Rf = 




   
N-4-(Piperidin-1-yl)benzyl-D-galactonoamidine (16x): Compound 28g (0.0464 g, 0.0654 
mmol); Pd/C (0.04 g) in 0.5 mL of trifluoroacetic acid and 5 mL ethanol; reaction time 40 h; 
ethanol amount for rinsing 2 mL each; compound 16x (0.0398 g, 0.1139 mmol, 174%); brown 
foam. Rf = 0.13 (SiO2, ethyl acetate/methanol = 5/1 v/v) 
 
N-4-Cyclohexylmethoxybenzyl-D-galactonoamidine (16y): Compound 28o (0.0912 g, 0.1234 
mmol); Pd/C (0.09 g) in 1 mL of trifluoroacetic acid and 5 mL ethanol; reaction time 72 h; 
ethanol amount for rinsing 2 mL each; compound 16y (0.0738 g, 0.1950 mmol, 158%); 
yellowish foam. Rf = 0.27 (SiO2, ethyl acetate/methanol = 5/1 v/v). 
 
N-4-(2-Hydroxyethyl)benzyl-D-galactonoamidine (16z): Compound 28n (0.0433 g, 0.0557 
mmol); Pd/C (0.04 g) in 0.5 mL of trifluoroacetic acid and 5 mL ethanol; reaction time 25 h; 
ethanol amount for rinsing 2 mL each; compound 16z (0.0385 g, 0.118 mmol, 211%); brown 





   
5: NMR spectra of new compounds 
 1H NMR (400.15 MHz, Acetone-d6)  
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Compound 29l 
 1H NMR (400.15 MHz, Methanol-d4)  
 







 13C NMR (100.6 MHz, Methanol-d4) 


















































   
Compound 28a 
 1H NMR (400.15 MHz, CD2Cl2) 





13C NMR (100.6 MHz, CD2Cl2) 




























































































   
Compound 28b 
1H NMR (400.15 MHz, CD2Cl2)  






13C NMR (100.6 MHz, CD2Cl2) 
 
























































































   
Compound 28c 
 1H NMR (400.15 MHz, CD2Cl2)  
 






 13C NMR (100.6 MHz, CD2Cl2) 












































































   
Compound 28d 
 1H NMR (400.15 MHz, CD2Cl2)  
 







13C NMR (100.6 MHz, CD2Cl2) 























































































   
Compound 28e 
 1H NMR (400.15 MHz, CD2Cl2)  






 13C NMR (100.6 MHz, CD2Cl2) 

























































































   
Compound 28f 
 1H NMR (400.15 MHz, CD2Cl2)  






 13C NMR (100.6 MHz, CD2Cl2) 
























































































   
Compound 28h 
 1H NMR (400.15 MHz, CD2Cl2)  
 






13C NMR (100.6 MHz, CD2Cl2) 
 
































































































   
Compound 28i 
 1H NMR (400.15 MHz, CD2Cl2)  
 
 






13C NMR (100.6 MHz, CD2Cl2) 
 































































































   
Compound 28i 
 1H NMR (400.15 MHz, CD2Cl2)  






 13C NMR (100.6 MHz, CD2Cl2)

































































































   
Compound 28j 
 1H NMR (400.15 MHz, CD2Cl2)  
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Compound 28k 
 1H NMR (400.15 MHz, CD2Cl2)  
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Compound 28l 
 1H NMR (400.15 MHz, CD2Cl2)  
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Compound 28m 
 1H NMR (400.15 MHz, CD2Cl2)  
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Compound 28n 
 1H NMR (400.15 MHz, CD2Cl2)  






13C NMR (100.6 MHz, CD2Cl2) 
































































































   
Compound 28o 
 1H NMR (400.15 MHz, CD2Cl2)  
 





 13C NMR (100.6 MHz, CD2Cl2) 





































































































   
Compound 28p 
 1H NMR (400.15 MHz, CD2Cl2)  
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Compound 28p’ 
1H NMR (400.15 MHz, CDCl3) 
IO175.001.esp





 13C NMR (100.6 MHz, CDCl3) 
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Compound 16k 
 1H NMR (400 MHz, D2O)  





 13C NMR (101 MHz, D2O + MeOD-d4) 
































































   
IO268 
 1H NMR (400 MHz, D2O)  
 





13C NMR (101 MHz, D2O + MeOD-d4) 

































































   
Compound 16m 
 1H NMR (400.15 MHz, D2O)  





 13C NMR (100.6 MHz, D2O + DMSO-d6) 
























































   
Compound 16n 
 1H NMR (400.15 MHz, D2O)  





 13C NMR (100.6 MHz, D2O + DMSO-d6) 
 







































   
Compound 16o 
 1H NMR (400 MHz, D2O)  





 13C NMR (101 MHz, D2O + MeOD-d4) 





















































   
Compound 16p 
 1H NMR (400.15 MHz, D2O)  





 13C NMR (100.6 MHz, D2O + DMSO-d6) 




































































   
Compound 16q 
 1H NMR (400.15 MHz, D2O)  





 13C NMR (100.6 MHz, D2O + DMSO-d6) 







































































   
Compound 16r 
 1H NMR (400.15 MHz, MeOD)  





 13C NMR (100.6 MHz, MeOD) 



























































   
Compound 16s 
 1H NMR (400 MHz, MeOD-d4)  







13C NMR (100.6 MHz, D2O + MeOD-d4) 
























































   
Compound 16t 
 1H NMR (400 MHz, D2O)  





13C NMR (100.6 MHz, D2O + MeOD-d4) 
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